

# CITATION REPORT

List of articles citing

## Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation

DOI: [10.1056/nejmoa1614359](https://doi.org/10.1056/nejmoa1614359)

New England Journal of Medicine, 2017, 377, 454-464.

Source: <https://exaly.com/paper-pdf/66427418/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
1382	Midostaurin for the treatment of acute myeloid leukemia. <b>2017</b> , 13, 1853-1871		7
1381	Reply to ABCG2 overexpression and deoxyadenosine analogue activity in acute myeloid leukemia. <b>2017</b> , 123, 4935-4936		1
1380	Overcoming mutational complexity in acute myeloid leukemia by inhibition of critical pathways. <b>2017</b> , 9,		9
1379	Midostaurin/PKC412 for the treatment of newly diagnosed FLT3 mutation-positive acute myeloid leukemia. <b>2017</b> , 10, 1033-1045		12
1378	Midostaurin treatment in FLT3-mutated acute myeloid leukemia and systemic mastocytosis. <b>2017</b> , 10, 1177-1189		15
1377	Inhibition of USP10 induces degradation of oncogenic FLT3. <b>2017</b> , 13, 1207-1215		57
1376	Midostaurin: A New Oral Agent Targeting FMS-Like Tyrosine Kinase 3-Mutant Acute Myeloid Leukemia. <b>2017</b> , 37, 1586-1599		11
1375	Which new agents will be incorporated into frontline therapy in acute myeloid leukemia?. <b>2017</b> , 30, 312-316		11
1374	AML in 2017: Advances in clinical practice. <b>2017</b> , 30, 283-286		9
1373	Cytarabine and daunorubicin for the treatment of acute myeloid leukemia. <b>2017</b> , 18, 1765-1780		57
1372	Long-term survival of sorafenib-treated FLT3-ITD-positive acute myeloid leukaemia patients relapsing after allogeneic stem cell transplantation. <b>2017</b> , 86, 233-239		49
1371	Midostaurin, enasidenib, CPX-351, gemtuzumab ozogamicin, and venetoclax bring new hope to AML. <b>2017</b> , 130, 2469-2474		94
1370	Relapsed/refractory acute myeloid leukemia: any progress?. <b>2017</b> , 29, 467-473		28
1369	Intensive consolidation with G-CSF support: Tolerability, safety, reduced hospitalization, and efficacy in acute myeloid leukemia patients ≥60 years. <b>2017</b> , 92, E567-E574		5
1368	Cutaneous Adverse Events of Targeted Therapies for Hematolymphoid Malignancies. <b>2017</b> , 17, 834-851		32
1367	Midostaurin and emerging FLT3 inhibitors for the treatment of adults with newly diagnosed acute myeloid leukemia with the FLT3 mutation. <b>2017</b> , 2, 307-320		2
1366	Proteomic and genomic integration identifies kinase and differentiation determinants of kinase inhibitor sensitivity in leukemia cells. <b>2017</b> ,		

1365	Targeting c-KIT (CD117) by dasatinib and radotinib promotes acute myeloid leukemia cell death. <b>2017</b> , 7, 15278	33
1364	Levosimendan in Cardiac Surgery. <i>New England Journal of Medicine</i> , <b>2017</b> , 377, 1900	59.2 3
1363	Midostaurin in FLT3-Mutated Acute Myeloid Leukemia. <i>New England Journal of Medicine</i> , <b>2017</b> , 377, 1903	39.2 21
1362	Haematological cancer: Feasible mutation-targeted therapy. <b>2017</b> , 14, 460	
1361	First Approved Kinase Inhibitor for AML. <b>2017</b> , 171, 981	8
1360	Pharmacologic agents to prevent and treat relapse after allogeneic hematopoietic cell transplantation. <b>2017</b> , 2017, 699-707	2
1359	The role of targeted therapy in the management of patients with AML. <b>2017</b> , 2017, 54-65	18
1358	Pharmacologic agents to prevent and treat relapse after allogeneic hematopoietic cell transplantation. <b>2017</b> , 1, 2473-2482	14
1357	Spotlight on midostaurin in the treatment of FLT3-mutated acute myeloid leukemia and systemic mastocytosis: design, development, and potential place in therapy. <b>2018</b> , 11, 175-182	8
1356	Targeting FLT3 Signaling in Childhood Acute Myeloid Leukemia. <b>2017</b> , 5, 248	16
1355	Emerging therapies for acute myeloid leukemia: translating biology into the clinic. <b>2017</b> , 2,	21
1354	The role of targeted therapy in the management of patients with AML. <b>2017</b> , 1, 2281-2294	38
1353	Molecular targeting in acute myeloid leukemia. <b>2017</b> , 15, 183	24
1352	mutations as a biomarker for myelodysplasia /myeloproliferative neoplasm overlap syndrome. <b>2017</b> , 5, 33	10
1351	Kinasehemmer verlängert das Leben. <b>2017</b> , 20, 34-34	
1350	Kinasehemmer verlängert Leben bei AML. <b>2017</b> , 20, 14-14	
1349	Azacitidine combined with the selective FLT3 kinase inhibitor crenolanib disrupts stromal protection and inhibits expansion of residual leukemia-initiating cells in -ITD AML with concurrent epigenetic mutations. <b>2017</b> , 8, 108738-108759	11
1348	Glutaminolysis is a metabolic dependency in FLT3 acute myeloid leukemia unmasked by FLT3 tyrosine kinase inhibition. <b>2018</b> , 131, 1639-1653	72

1347	Minimal residual disease (MRD) monitoring and mutational landscape in AML with RUNX1-RUNX1T1: a study on 134 patients. <b>2018</b> , 32, 2270-2274	16
1346	Minimal residual disease as a biomarker for outcome prediction and therapy optimization in acute myeloid leukemia. <b>2018</b> , 11, 307-313	15
1345	High-dose melphalan-based sequential conditioning chemotherapy followed by allogeneic haematopoietic stem cell transplantation in adult patients with relapsed or refractory acute myeloid leukaemia. <b>2018</b> , 180, 840-853	9
1344	Universal genetic testing for inherited susceptibility in children and adults with myelodysplastic syndrome and acute myeloid leukemia: are we there yet?. <b>2018</b> , 32, 1482-1492	33
1343	Can we forecast induction failure in acute myeloid leukemia?. <b>2018</b> , 103, 375-377	4
1342	Control in dormancy or eradication of cancer stem cells: Mathematical modeling and stability issues. <b>2018</b> , 449, 103-123	3
1341	Improving the detection of patients with inherited predispositions to hematologic malignancies using next-generation sequencing-based leukemia prognostication panels. <b>2018</b> , 124, 2704-2713	29
1340	Proteomic and genomic integration identifies kinase and differentiation determinants of kinase inhibitor sensitivity in leukemia cells. <b>2018</b> , 32, 1818-1822	23
1339	Acute myelogenous leukemia in adolescents and young adults. <b>2018</b> , 65, e27089	29
1338	Genetic alterations crossing the borders of distinct hematopoietic lineages and solid tumors: Diagnostic challenges in the era of high-throughput sequencing in hemato-oncology. <b>2018</b> , 126, 64-79	6
1337	No Mutation Left Behind: The Impact of Reporting Recurrent Genetic Abnormalities on Outcomes of Patients with Acute Myeloid Leukemia. <b>2018</b> , 139, 128-130	1
1336	Myeloid Malignancies. <b>2018</b> , 397-421	1
1335	Allogeneic stem cell transplantation for mutated acute myeloid leukemia in first complete remission: does age really matter?. <b>2018</b> , 103, 191-193	1
1334	Interpretation of clinical endpoints in trials of acute myeloid leukemia. <b>2018</b> , 68, 32-39	22
1333	Induction chemotherapy in acute myeloid leukaemia: origins and emerging directions. <b>2018</b> , 25, 67-74	3
1332	Inhibition of FLT3 and PIM Kinases by EC-70124 Exerts Potent Activity in Preclinical Models of Acute Myeloid Leukemia. <b>2018</b> , 17, 614-624	10
1331	Prospective randomization of post-remission therapy comparing autologous peripheral blood stem cell transplantation versus high-dose cytarabine consolidation for acute myelogenous leukemia in first remission. <b>2018</b> , 107, 468-477	6
1330	Prognostic analysis according to the 2017 ELN risk stratification by genetics in adult acute myeloid leukemia patients treated in the Japan Adult Leukemia Study Group (JALSG) AML201 study. <b>2018</b> , 66, 20-27	31

1329	Tyrosine kinase inhibitors and immune checkpoint blockade in allogeneic hematopoietic cell transplantation. <b>2018</b> , 131, 1073-1080	18
1328	Therapeutic choices after hypomethylating agent resistance for myelodysplastic syndromes. <b>2018</b> , 25, 146-153	18
1327	The most novel of the novel agents for acute myeloid leukemia. <b>2018</b> , 25, 81-89	7
1326	New therapeutic strategies for high-risk acute myeloid leukemia. <b>2018</b> , 25, 90-94	6
1325	FLT3 inhibitors in acute myeloid leukemia: Choosing the best when the optimal does not exist. <b>2018</b> , 93, 553-563	10
1324	Evaluating the Impact of the Addition of Cladribine to Standard Acute Myeloid Leukemia Induction Therapy. <b>2018</b> , 52, 439-445	8
1323	Allogeneic stem cell transplantation benefits for patients ≥60 years with acute myeloid leukemia and internal tandem duplication: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <b>2018</b> , 103, 256-265	11
1322	A concise review of BCL-2 inhibition in acute myeloid leukemia. <b>2018</b> , 11, 145-154	14
1321	Risk-stratified therapy for children with FLT3-ITD-positive acute myeloid leukemia: results from the JPLSG AML-05 study. <b>2018</b> , 107, 586-595	11
1320	The rocky road to personalized medicine in acute myeloid leukaemia. <b>2018</b> , 22, 1411-1427	15
1319	Genomics in childhood acute myeloid leukemia comes of age. <b>2018</b> , 24, 7-9	10
1318	The bone-marrow niche in MDS and MGUS: implications for AML and MM. <b>2018</b> , 15, 219-233	81
1317	Personalizing initial therapy in acute myeloid leukemia: incorporating novel agents into clinical practice. <b>2018</b> , 9, 109-121	9
1316	High dose daunorubicin: New standard of care for FLT3 ITD mutant AML. <b>2018</b> , 69, 87-88	1
1315	High -mutant allele burden at diagnosis predicts unfavorable outcomes in de novo AML. <b>2018</b> , 131, 2816-2825	50
1314	Phase 1/2 trial of GCLAM with dose-escalated mitoxantrone for newly diagnosed AML or other high-grade myeloid neoplasms. <b>2018</b> , 32, 2352-2362	21
1313	Sorafenib Dose Recommendation in Acute Myeloid Leukemia Based on Exposure-FLT3 Relationship. <b>2018</b> , 11, 435-443	11
1312	From genomics to targeted treatment in haematological malignancies: a focus on acute myeloid leukaemia. <b>2018</b> , 18, s47-s53	4

1311	Current status and trends in the diagnostics of AML and MDS. <b>2018</b> , 32, 508-519	23
1310	Advancements in the management of medically less-fit and older adults with newly diagnosed acute myeloid leukemia. <b>2018</b> , 19, 865-882	11
1309	Acute myeloid leukemia induction with cladribine: Outcomes by age and leukemia risk. <b>2018</b> , 68, 72-78	6
1308	RET-mediated autophagy suppression as targetable co-dependence in acute myeloid leukemia. <b>2018</b> , 32, 2189-2202	33
1307	A novel regimen for relapsed/refractory adult acute myeloid leukemia using a partial tandem duplication targeted therapy: results of phase 1 study NCI 8485. <b>2018</b> , 103, 982-987	11
1306	Comparison of anthracyclines used for induction chemotherapy in patients with FLT3-ITD-mutated acute myeloid leukemia. <b>2018</b> , 68, 51-56	12
1305	Results of a phase 1 study of quizartinib as maintenance therapy in subjects with acute myeloid leukemia in remission following allogeneic hematopoietic stem cell transplant. <b>2018</b> , 93, 222-231	74
1304	Occurrence of graft-versus-host disease increases mortality after umbilical cord blood transplantation for acute myeloid leukaemia: a report from Eurocord and the ALWP of the EBMT. <b>2018</b> , 283, 178-189	17
1303	RSK2 is a new Pim2 target with pro-survival functions in FLT3-ITD-positive acute myeloid leukemia. <b>2018</b> , 32, 597-605	14
1302	The importance of FLT3 mutational analysis in acute myeloid leukemia. <b>2018</b> , 59, 2273-2286	48
1301	The impact of age, NPM1, and FLT3 allelic ratio in patients with acute myeloid leukemia. <b>2018</b> , 131, 1148-1153	27
1300	A novel irreversible FLT3 inhibitor, FF-10101, shows excellent efficacy against AML cells with mutations. <b>2018</b> , 131, 426-438	64
1299	Dueling for dual inhibition: Means to enhance effectiveness of PI3K/Akt/mTOR inhibitors in AML. <b>2018</b> , 32, 235-248	37
1298	Midostaurin in Combination With Standard Chemotherapy for Treatment of Newly Diagnosed FMS-Like Tyrosine Kinase 3 (FLT3) Mutation-Positive Acute Myeloid Leukemia. <b>2018</b> , 52, 364-369	2
1297	Advances in targeted therapy for acute myeloid leukaemia. <b>2018</b> , 180, 484-500	59
1296	Targeting oncoproteins for degradation by small molecules in myeloid leukemia. <b>2018</b> , 59, 2297-2304	2
1295	Midostaurin, a Natural Product-Derived Kinase Inhibitor Recently Approved for the Treatment of Hematological Malignancies. <b>2018</b> , 57, 477-478	11
1294	Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies. <b>2018</b> , 93, 401-407	229

1293	Hypomethylating agents for treatment and prevention of relapse after allogeneic blood stem cell transplantation. <b>2018</b> , 107, 138-150	39
1292	Phase 1 study of quizartinib in combination with induction and consolidation chemotherapy in patients with newly diagnosed acute myeloid leukemia. <b>2018</b> , 93, 213-221	59
1291	Improving Overall Survival in Older Adults With Acute Myeloid Leukemia: Subpopulations Matter. <b>2018</b> , 36, 3186-3188	1
1290	CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia. <b>2018</b> , 36, 2684-2692	446
1289	A phase 1 trial evaluating thioridazine in combination with cytarabine in patients with acute myeloid leukemia. <b>2018</b> , 2, 1935-1945	17
1288	Improved Survival by Adding Lomustine to Conventional Chemotherapy for Elderly Patients With AML Without Unfavorable Cytogenetics: Results of the LAM-SA 2007 FILO Trial. <b>2018</b> , 36, 3203-3210	18
1287	Rationale and Design of the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. <b>2018</b> , 2018,	53
1286	Personalisierte Medizin in der Hämatoonkologie. <b>2018</b> , 21, 49-55	
1285	Disruption of MAPK1 expression in the ERK signalling pathway and the RUNX1-RUNX1T1 fusion gene attenuate the differentiation and proliferation and induces the growth arrest in t(8;21) leukaemia cells. <b>2019</b> , 41, 2027-2040	8
1284	Midostaurin reduces Regulatory T cells markers in Acute Myeloid Leukemia. <b>2018</b> , 8, 17544	14
1283	Standard- oder Therapieverändernde Erkenntnisse in der Hämatologie. <b>2018</b> , 47, 550-556	
1282	Nuclear transport inhibition in acute myeloid leukemia: recent advances and future perspectives. <b>2018</b> , 7, IJH04	13
1281	Combined inhibition of receptor tyrosine and p21-activated kinases as a therapeutic strategy in childhood ALL. <b>2018</b> , 2, 2554-2567	10
1280	Molecular landscape and targeted therapy of acute myeloid leukemia. <b>2018</b> , 6, 32	20
1279	Pattern and prognostic value of FLT3-ITD mutations in Chinese de novo adult acute myeloid leukemia. <b>2018</b> , 109, 3981-3992	6
1278	Novel Agents for Acute Myeloid Leukemia. <b>2018</b> , 10,	16
1277	Prognostic impact of low allelic ratio ITD and mutation in acute myeloid leukemia. <b>2018</b> , 2, 2744-2754	66
1276	Clinical use of FLT3 inhibitors in acute myeloid leukemia. <b>2018</b> , 11, 7041-7052	21

1275	Therapeutic Vulnerabilities in -Mutant AML Unmasked by Palbociclib. <b>2018</b> , 19,	7
1274	The return of gemtuzumab ozogamicin: a humanized anti-CD33 monoclonal antibody-drug conjugate for the treatment of newly diagnosed acute myeloid leukemia. <b>2018</b> , 11, 8265-8272	24
1273	Eradication of Central Nervous System Leukemia of T-Cell Origin with a Brain-Permeable LSD1 Inhibitor. <b>2019</b> , 25, 1601-1611	8
1272	FLT3 inhibitors in acute myeloid leukemia. <b>2018</b> , 11, 133	71
1271	Myelodysplastic syndromes and acute myeloid leukemias in the elderly. <b>2018</b> , 58, 28-32	3
1270	Toward the potential cure of leukemias in the next decade. <b>2018</b> , 124, 4301-4313	20
1269	Dual Targeting of Aurora Kinases with AMG 900 Exhibits Potent Preclinical Activity Against Acute Myeloid Leukemia with Distinct Post-Mitotic Outcomes. <b>2018</b> , 17, 2575-2585	9
1268	A comprehensive review of protein kinase inhibitors for cancer therapy. <b>2018</b> , 18, 1249-1270	87
1267	Improving consolidation therapy in acute myeloid leukemia - a tough nut to crack. <b>2018</b> , 103, 1579-1581	1
1266	Sequential high-dose cytarabine and mitoxantrone (S-HAM) versus standard double induction in acute myeloid leukemia-a phase 3 study. <b>2018</b> , 32, 2558-2571	11
1265	Which novel agents for acute myeloid leukemia are likely to change practice?. <b>2018</b> , 31, 391-395	3
1264	What FLT3 inhibitor holds the greatest promise?. <b>2018</b> , 31, 401-404	9
1263	Cost-effectiveness analysis for midostaurin versus standard of care in acute myeloid leukemia in the United Kingdom. <b>2018</b> , 16, 33	5
1262	Allogeneic Hematopoietic Stem Cell Transplantation for Older Patients With Acute Myeloid Leukemia. <b>2018</b> , 19, 63	10
1261	Incorporating newer agents in the treatment of acute myeloid leukemia. <b>2018</b> , 74, 113-120	6
1260	Brñsted Acid Catalyzed One-Pot Benzannulation of 2-Alkenylindoles under Aerial Oxidation: A Route to Carbazoles and Indolo[2,3- a]carbazole Alkaloids. <b>2018</b> , 20, 6920-6924	23
1259	Acute myeloid leukemia: 2019 update on risk-stratification and management. <b>2018</b> , 93, 1267-1291	171
1258	Functional genomic landscape of acute myeloid leukaemia. <b>2018</b> , 562, 526-531	391



1257	SOHO State of the Art Update and Next Questions: IDH Therapeutic Targeting in AML. <b>2018</b> , 18, 769-772	14
1256	SRSF2 mutations in myelodysplasia/myeloproliferative neoplasms. <b>2018</b> , 6, 29	5
1255	Phase I/II study on cytarabine and idarubicin combined with escalating doses of clofarabine in newly diagnosed patients with acute myeloid leukaemia and high risk for induction failure (AML17-10 CIARA trial). <b>2018</b> , 183, 235-241	2
1254	Targeting Oncogenic Signaling in Mutant FLT3 Acute Myeloid Leukemia: The Path to Least Resistance. <b>2018</b> , 19,	30
1253	New Food and Drug Administration-Approved and Emerging Novel Treatment Options for Acute Myeloid Leukemia. <b>2018</b> , 38, 1143-1154	12
1252	[AML in Adults - An Update on Diagnosis, Risk Classification and Therapy]. <b>2018</b> , 143, 1297-1303	1
1251	FLT3-Inhibitoren in der Therapie der akuten myeloischen Leukämie. <b>2018</b> , 13, 182-190	0
1250	Atypical Phenotype and Treatment Response Pattern in a Patient with FIP1L1-PDGFR Mutation. <b>2018</b> , 140, 67-70	0
1249	Recently approved therapies in acute myeloid leukemia: A complex treatment landscape. <b>2018</b> , 73, 58-66	38
1248	AML Debate: Use Gemtuzumab Ozogamicin in Most AML Patients vs. Use in CBF Patients or Not at All? Pro. <b>2018</b> , 18, S61-S63	
1247	Cytotoxic therapy in acute myeloid leukemia: not quite dead yet. <b>2018</b> , 2018, 51-62	7
1246	Midostaurin: its odyssey from discovery to approval for treating acute myeloid leukemia and advanced systemic mastocytosis. <b>2018</b> , 2, 444-453	88
1245	Ten-year outcome of patients with acute myeloid leukemia not treated with allogeneic transplantation in first complete remission. <b>2018</b> , 2, 1645-1650	58
1244	Impact of FLT3 Receptor (CD135) Detection by Flow Cytometry on Clinical Outcome of Adult Acute Myeloid Leukemia Patients. <b>2018</b> , 18, 541-547	8
1243	Targeting the Pathway in Acute Myeloid Leukemia. <b>2018</b> , 24, 4931-4936	20
1242	Venetoclax and low-dose cytarabine induced complete remission in a patient with high-risk acute myeloid leukemia: a case report. <b>2018</b> , 12, 593-599	5
1241	Tyrosine kinase inhibitor-induced defects in DNA repair sensitize FLT3(ITD)-positive leukemia cells to PARP1 inhibitors. <b>2018</b> , 132, 67-77	38
1240	Staurosporine Increases Lentiviral Vector Transduction Efficiency of Human Hematopoietic Stem and Progenitor Cells. <b>2018</b> , 9, 313-322	12

1239	How I treat older patients with acute myeloid leukemia. <b>2018</b> , 124, 2472-2483	5
1238	Predictive and Prognostic Markers in Adults With Acute Myeloid Leukemia: A Single-Institution Experience. <b>2018</b> , 18, e287-e294	4
1237	Targeted Treatments for Hematological Cancers. <b>2018</b> , 259-312	
1236	FLT3 inhibitors for relapsed or refractory acute myeloid leukaemia. <b>2018</b> , 19, 849-850	3
1235	Molecular Minimal Residual Disease Testing in Acute Myeloid Leukemia: A Review for the Practicing Clinician. <b>2018</b> , 18, 636-647	5
1234	Reformulating acute myeloid leukemia: liposomal cytarabine and daunorubicin (CPX-351) as an emerging therapy for secondary AML. <b>2018</b> , 11, 3425-3434	33
1233	Acute myeloid leukaemia. <b>2018</b> , 392, 593-606	280
1232	Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high-risk MDS: Phase 2 study results. <b>2018</b> , 93, 1301-1310	75
1231	Midostaurin: A Multiple Tyrosine Kinases Inhibitor in Acute Myeloid Leukemia and Systemic Mastocytosis. <b>2018</b> , 212, 199-214	9
1230	Non-internal tandem duplication (ITD), non-tyrosine kinase domain (TKD) FLT3 mutations in myeloid malignancies: A brief report of 10 patients. <b>2018</b> , 72, 1-4	0
1229	Application of multi-state models in cancer clinical trials. <b>2018</b> , 15, 489-498	20
1228	A next-generation sequencing-based assay for minimal residual disease assessment in AML patients with -ITD mutations. <b>2018</b> , 2, 825-831	69
1227	Small Molecules in Hematology. <b>2018</b> ,	4
1226	Bridging Strategies to Allogeneic Transplant for Older AML Patients. <b>2018</b> , 10,	4
1225	Targeting FLT3 Mutations in Acute Myeloid Leukemia. <b>2018</b> , 7,	24
1224	Immunosenescence and Immunotherapy in Elderly Acute Myeloid Leukemia Patients: Time for a Biology-Driven Approach. <b>2018</b> , 10,	7
1223	Integrative genomic analysis of adult mixed phenotype acute leukemia delineates lineage associated molecular subtypes. <b>2018</b> , 9, 2670	47
1222	Association of Second Allogeneic Hematopoietic Cell Transplant vs Donor Lymphocyte Infusion With Overall Survival in Patients With Acute Myeloid Leukemia Relapse. <b>2018</b> , 4, 1245-1253	53

1221	Precision therapy for acute myeloid leukemia. <b>2018</b> , 11, 3	51
1220	Adding dasatinib to intensive treatment in core-binding factor acute myeloid leukemia-results of the AMLSG 11-08 trial. <b>2018</b> , 32, 1621-1630	53
1219	New and emerging therapies for acute myeloid leukaemia. <b>2018</b> , 66, 1088-1095	16
1218	n-3 Polyunsaturated fatty acids induce acute myeloid leukemia cell death associated with mitochondrial glycolytic switch and Nrf2 pathway activation. <b>2018</b> , 136, 45-55	17
1217	Recent advances in the understanding and treatment of acute myeloid leukemia. <b>2018</b> , 7,	34
1216	Comparison of the Kinase Profile of Midostaurin (Rydapt) with That of Its Predominant Metabolites and the Potential Relevance of Some Newly Identified Targets to Leukemia Therapy. <b>2018</b> , 57, 5576-5590	9
1215	Use of FLT3 inhibitors in acute myeloid leukemia remission induction or salvage therapy: systematic review and meta-analysis. <b>2018</b> , 10, 2635-2652	4
1214	Staurosporine Derivatives Generated by Pathway Engineering in a Heterologous Host and Their Cytotoxic Selectivity. <b>2018</b> , 81, 1745-1751	4
1213	The role of FLT3 inhibitors as maintenance therapy following hematopoietic stem cell transplant. <b>2018</b> , 10, 26-36	8
1212	Cladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trial. <b>2018</b> , 5, e411-e421	43
1211	Advances in treatment formulations for acute myeloid leukemia. <b>2018</b> , 23, 1936-1949	32
1210	Phase 2b study of 2 dosing regimens of quizartinib monotherapy in -ITD-mutated, relapsed or refractory AML. <b>2018</b> , 132, 598-607	94
1209	Novel Approaches to Acute Myeloid Leukemia Immunotherapy. <b>2018</b> , 24, 5502-5515	35
1208	New drugs in AML: uses and abuses. <b>2018</b> , 32, 1479-1481	9
1207	Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies. <b>2018</b> , 5, e563-e598	62
1206	Update on cardio-oncology: Novel cancer therapeutics and associated cardiotoxicities. <b>2019</b> , 29, 29-39	29
1205	Preclinical evaluation of the selective small-molecule UBA1 inhibitor, TAK-243, in acute myeloid leukemia. <b>2019</b> , 33, 37-51	34
1204	Current and evolving understanding of atypical chronic myeloid leukemia. <b>2019</b> , 33, 74-81	15

1203	An Anti-CLL-1 Antibody-Drug Conjugate for the Treatment of Acute Myeloid Leukemia. <b>2019</b> , 25, 1358-1368	38
1202	Genetic and epigenetic determinants of AML pathogenesis. <b>2019</b> , 56, 84-89	34
1201	Post-remission strategies for the prevention of relapse following allogeneic hematopoietic cell transplantation for high-risk acute myeloid leukemia: expert review from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <b>2019</b> , 54, 519-530	36
1200	Neue Entwicklungen der Systemtherapie maligner Erkrankungen. <b>2019</b> , 25, 68-76	
1199	Which are the most promising targets for minimal residual disease-directed therapy in acute myeloid leukemia prior to allogeneic stem cell transplant?. <b>2019</b> , 104, 1521-1531	13
1198	Genetic Characterization and Prognostic Relevance of Acquired Uniparental Disomies in Cytogenetically Normal Acute Myeloid Leukemia. <b>2019</b> , 25, 6524-6531	5
1197	Molecular landscape in adult acute myeloid leukemia: where we are where we going?. <b>2019</b> , 4, 17-17	1
1196	Safety and efficacy of oral panobinostat plus chemotherapy in patients aged 65 years or younger with high-risk acute myeloid leukemia. <b>2019</b> , 85, 106197	8
1195	Maintenance therapy in AML: The past, the present and the future. <b>2019</b> , 94, 1254-1265	24
1194	Diagnostik und Therapie der akuten myeloischen Leukämie. <b>2019</b> , 14, 386-397	
1193	Prinzipien der AML-Therapie. <b>2019</b> , 22, 15-18	
1192	Comparison of effects of midostaurin, crenolanib, quizartinib, gilteritinib, sorafenib and BLU-285 on oncogenic mutants of KIT, CBL and FLT3 in haematological malignancies. <b>2019</b> , 187, 488-501	17
1191	Combining gene mutation with gene expression analysis improves outcome prediction in acute promyelocytic leukemia. <b>2019</b> , 134, 951-959	16
1190	Inhibition of Bcl-2 Synergistically Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Preclinical Models of FLT3-Mutated Acute Myeloid Leukemia. <b>2019</b> , 25, 6815-6826	53
1189	Sorafenib plus intensive chemotherapy improves survival in patients with newly diagnosed, FLT3-internal tandem duplication mutation-positive acute myeloid leukemia. <b>2019</b> , 125, 3755-3766	24
1188	Novel therapy in Acute myeloid leukemia (AML): moving toward targeted approaches. <b>2019</b> , 10, 2040620719860645	6
1187	Reduced Expression of Sprouty1 Contributes to the Aberrant Proliferation and Impaired Apoptosis of Acute Myeloid Leukemia Cells. <b>2019</b> , 8,	4
1186	The fragility of phase 3 trials supporting FDA-approved anticancer medicines: a retrospective analysis. <b>2019</b> , 20, 1065-1069	41

1185	Acute Myeloid Leukemia: from Mutation Profiling to Treatment Decisions. <b>2019</b> , 14, 386-394	12
1184	Novel approaches to treating advanced systemic mastocytosis. <b>2019</b> , 11, 77-92	13
1183	MRD in AML: The Role of New Techniques. <b>2019</b> , 9, 655	57
1182	Clinical considerations for the use of FLT3 inhibitors in acute myeloid leukemia. <b>2019</b> , 141, 125-138	28
1181	Acute Myeloid Leukemia: Update on Upfront Therapy in Elderly Patients. <b>2019</b> , 21, 71	8
1180	Differences in Mutational Profile between Follicular Thyroid Carcinoma and Follicular Thyroid Adenoma Identified Using Next Generation Sequencing. <b>2019</b> , 20,	17
1179	Availability of FLT3 inhibitors: how do we use them?. <b>2019</b> , 134, 741-745	28
1178	Midostaurin Reverses ABCB1-Mediated Multidrug Resistance, an Study. <b>2019</b> , 9, 514	22
1177	Cyclin-dependent kinase (CDK) 9 and 4/6 inhibitors in acute myeloid leukemia (AML): a promising therapeutic approach. <b>2019</b> , 28, 989-1001	21
1176	Antileukemic Efficacy in Vitro of Talazoparib and APE1 Inhibitor III Combined with Decitabine in Myeloid Malignancies. <b>2019</b> , 11,	8
1175	Post-remission therapy in acute myeloid leukemia: Are we ready for an individualized approach?. <b>2019</b> , 32, 101102	4
1174	Maintenance therapy after allogeneic hematopoietic cell transplantation for acute myeloid leukemia. <b>2019</b> , 32, 101109	8
1173	Enabling highly efficient photocatalytic hydrogen generation and organics degradation via a perovskite solar cell-assisted semiconducting nanocomposite photoanode. <b>2019</b> , 7, 165-171	25
1172	Allogeneic transplant for - mutated AML: a focus on inhibitors before, during, and after transplant. <b>2019</b> , 10, 2040620719882666	16
1171	Loss of FBXO9 Enhances Proteasome Activity and Promotes Aggressiveness in Acute Myeloid Leukemia. <b>2019</b> , 11,	7
1170	Characteristics of Sweet's syndrome associated with novel acute myeloid leukemia targeted drugsâ€”Midostaurin and Enasidenib. <b>2019</b> , 2, e61	4
1169	Targeting Apoptotic Pathways in Acute Myeloid Leukaemia. <b>2019</b> , 11,	6
1168	Identification of a Multitargeted Tyrosine Kinase Inhibitor for the Treatment of Gastrointestinal Stromal Tumors and Acute Myeloid Leukemia. <b>2019</b> , 62, 11135-11150	3

1167	Targeted Therapies for Pediatric AML: Gaps and Perspective. <b>2019</b> , 7, 463		27
1166	[What is recommended in the treatment of acute myeloid leukemia?]. <b>2019</b> , 60, 1240-1250		
1165	Molecular diagnostics and risk assessment in myeloid malignancies. <b>2019</b> , 49-58		
1164	Clinical and economic analysis of patients with acute myeloid leukemia by FLT3 status and midostaurin use at a Comprehensive Cancer Center. <b>2019</b> , 87, 106262		
1163	Detection and Quantification of FLT3 Internal Tandem Duplication Mutations Do Not Vary Significantly Between Whole Blood and Blast-Enriched Samples. <b>2020</b> , 153, 251-257		
1162	Midostaurin In Acute Myeloid Leukemia: An Evidence-Based Review And Patient Selection. <b>2019</b> , 11, 8817-8828		11
1161	Gilteritinib or Chemotherapy for Relapsed or Refractory -Mutated AML. <i>New England Journal of Medicine</i> , <b>2019</b> , 381, 1728-1740	59.2	413
1160	Isoliquiritigenin, an Orally Available Natural FLT3 Inhibitor from Licorice, Exhibits Selective Anti-Acute Myeloid Leukemia Efficacy In Vitro and In Vivo. <b>2019</b> , 96, 589-599		2
1159	A personalized approach to acute myeloid leukemia therapy: current options. <b>2019</b> , 12, 167-179		5
1158	Multi-study reanalysis of 2,213 acute myeloid leukemia patients reveals age- and sex-dependent gene expression signatures. <b>2019</b> , 9, 12413		3
1157	An evaluation of enasidenib for the treatment of acute myeloid leukemia. <b>2019</b> , 20, 1935-1942		3
1156	Gilteritinib for the treatment of relapsed and/or refractory FLT3-mutated acute myeloid leukemia. <b>2019</b> , 12, 841-849		7
1155	Recent advances in the synthesis of carbazoles from indoles. <b>2019</b> , 17, 8330-8342		34
1154	Emerging Epigenetic Therapeutic Targets in Acute Myeloid Leukemia. <b>2019</b> , 9, 850		10
1153	Overcoming adaptive therapy resistance in AML by targeting immune response pathways. <b>2019</b> , 11,		25
1152	Hematological malignancies and molecular targeting therapy. <b>2019</b> , 862, 172641		18
1151	Antibody Therapies for Acute Myeloid Leukemia: Unconjugated, Toxin-Conjugated, Radio-Conjugated and Multivalent Formats. <b>2019</b> , 8,		26
1150	First Results from a Screening of 300 Naturally Occurring Compounds: 4,6-dibromo-2-(2',4'-dibromophenoxy)phenol, 4,5,6-tribromo-2-(2',4'-dibromophenoxy)phenol, and 5-epi-nakijinone Q as Substances with the Potential for Anticancer Therapy. <b>2019</b> , 17,		4

1149	Recent drug approvals for acute myeloid leukemia. <b>2019</b> , 12, 100	66
1148	Gilteritinib: a novel FLT3 inhibitor for acute myeloid leukemia. <b>2019</b> , 7, 19	29
1147	Midostaurin in combination with intensive chemotherapy is safe and associated with improved remission rates and higher transplantation rates in first remission-a multi-center historical control study. <b>2019</b> , 98, 2711-2717	10
1146	Association between increased mutation rates in DNMT3A and FLT3-ITD and poor prognosis of patients with acute myeloid leukemia. <b>2019</b> , 18, 3117-3124	4
1145	Quality of Response in Acute Myeloid Leukemia: The Role of Minimal Residual Disease. <b>2019</b> , 11,	4
1144	Comparison of survivor scores for differentiation therapy of cancer to those for checkpoint inhibition: Half full or half empty. <b>2019</b> , 41, 1010428319873749	2
1143	Pediatric Acute Myeloid Leukemia (AML): From Genes to Models Toward Targeted Therapeutic Intervention. <b>2019</b> , 7, 401	14
1142	Non-allogeneic immunotherapy in acute myeloid leukaemia. <b>2019</b> , 6, e443-e444	
1141	Functional characterization of the halogenase SpmH and discovery of new deschloro-tryptophan dimers. <b>2019</b> , 17, 1053-1057	14
1140	Formal [4 + 2] benzannulation of 2-alkenyl indoles with aldehydes: a route to structurally diverse carbazoles and bis-carbazoles. <b>2019</b> , 17, 1822-1826	12
1139	Amino alkynylisoquinoline and alkynyl naphthyridine compounds potently inhibit acute myeloid leukemia proliferation in mice. <b>2019</b> , 40, 231-239	6
1138	Daunorubicin and cytarabine for certain types of poor-prognosis acute myeloid leukemia: a systematic literature review. <b>2019</b> , 12, 197-218	6
1137	Advancing treatment of acute myeloid leukemia: the future of FLT3 inhibitors. <b>2019</b> , 19, 273-286	16
1136	[Some important breakthroughs in oncology and hematology in 2018: A selection by the editorial board of Bulletin du Cancer]. <b>2019</b> , 106, 12-23	0
1135	Novel Approaches for Systemic Mastocytosis. <b>2019</b> , 26, 112-118	4
1134	Efficacy and Feasibility of Sorafenib as a Maintenance Agent After Allogeneic Hematopoietic Stem Cell Transplantation for Fms-like Tyrosine Kinase 3 Mutated Acute Myeloid Leukemia: An Update. <b>2019</b> , 19, 506-508	25
1133	FLT3 overexpression in acute leukaemias: New insights into the search for molecular mechanisms. <b>2019</b> , 1872, 80-88	5
1132	Side effects from acute myeloid leukemia treatment: results from a national survey. <b>2019</b> , 35, 1965-1970	15

1131	Novel meriolin derivatives as rapid apoptosis inducers. <b>2019</b> , 27, 3463-3468	4
1130	From DNA Sequencing to Clinical Trials: Finding New Targeted Drugs for Acute Myeloid Leukemia. <b>2019</b> , 79, 1177-1186	5
1129	Recent Treatment Advances and the Role of Nanotechnology, Combination Products, and Immunotherapy in Changing the Therapeutic Landscape of Acute Myeloid Leukemia. <b>2019</b> , 36, 125	32
1128	Novel treatments for relapsed/refractory acute myeloid leukemia with mutations. <b>2019</b> , 12, 621-640	1
1127	Daunorubicin-cytarabine liposome (CPX-351) in the management of newly diagnosed secondary AML: A new twist on an old cocktail. <b>2019</b> , 32, 127-133	13
1126	Acute Myeloid Leukemia Mutations: Therapeutic Implications. <b>2019</b> , 20,	11
1125	Dual FLT3 inhibitors: Against the drug resistance of acute myeloid leukemia in recent decade. <b>2019</b> , 178, 468-483	20
1124	Gilteritinib for the treatment of patients with FLT3 mutated relapsed or refractory acute myeloid leukemia. <b>2019</b> , 4, 105-112	2
1123	Allogeneic Hematopoietic Cell Transplantation Outcomes in Patients Carrying Isocitrate Dehydrogenase Mutations. <b>2019</b> , 19, e400-e405	3
1122	Investigation of screening method for DNMT3A mutations by high-resolution melting analysis in acute myeloid leukemia. <b>2019</b> , 41, 593-600	3
1121	Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial. <b>2019</b> , 20, 984-997	182
1120	Oral targeted agent versus chemotherapy in acute myeloid leukaemia. <b>2019</b> , 20, 896-898	
1119	Acute Myeloid Leukemia in Young Adults: Does Everyone Need a Transplant?. <b>2019</b> , 15, 315-320	2
1118	Healthcare expenses for treatment of acute myeloid leukemia. <b>2019</b> , 12, 641-650	9
1117	Functional Properties of Mutations Are Associated with Differential Clinical Outcomes and Response to Targeted Therapeutics in CBF Acute Myeloid Leukemia. <b>2019</b> , 25, 5038-5048	19
1116	Precision medicine and novel molecular target therapies in acute myeloid leukemia: the background of hematologic malignancies (HM)-SCREEN-Japan 01. <b>2019</b> , 24, 893-898	6
1115	MDM2 antagonists as a novel treatment option for acute myeloid leukemia: perspectives on the therapeutic potential of idasanutlin (RG7388). <b>2019</b> , 12, 2903-2910	34
1114	Genome-scale drop-out screens to identify cancer cell vulnerabilities in AML. <b>2019</b> , 54, 83-87	1



1113	Natural Products and Acute Myeloid Leukemia: A Review Highlighting Mechanisms of Action. <b>2019</b> , 11,	21
1112	Incorporating FLT3 inhibitors in the frontline treatment of FLT3 mutant acute myeloid leukemia. <b>2019</b> , 32, 154-162	10
1111	Allogeneic Stem Cell Transplantation in Patients With FLT3-ITD Mutated AML: Transplantation in CR1 Is the Decisive Factor for Good Outcome. <b>2019</b> , 19, 462-469	1
1110	Heterogeneity in refractory acute myeloid leukemia. <b>2019</b> , 116, 10494-10503	22
1109	Dual effect of the broad spectrum kinase inhibitor midostaurin in acute and latent HIV-1 infection. <b>2019</b> , 168, 18-27	5
1108	What role can next-generation sequencing play in myelodysplastic syndrome care?. <b>2019</b> , 12, 379-382	1
1107	Clonal Selection with RAS Pathway Activation Mediates Secondary Clinical Resistance to Selective FLT3 Inhibition in Acute Myeloid Leukemia. <b>2019</b> , 9, 1050-1063	148
1106	High expression of miR-25 predicts favorable chemotherapy outcome in patients with acute myeloid leukemia. <b>2019</b> , 19, 122	2
1105	getITD for FLT3-ITD-based MRD monitoring in AML. <b>2019</b> , 33, 2535-2539	20
1104	Combining structure- and property-based optimization to identify selective FLT3-ITD inhibitors with good antitumor efficacy in AML cell inoculated mouse xenograft model. <b>2019</b> , 176, 248-267	5
1103	Trends in Clinical Benefits and Costs of Novel Therapeutics in AML: at What Price Does Progress Come?. <b>2019</b> , 14, 171-178	11
1102	Can we incorporate MRD assessment into clinical practice in AML?. <b>2019</b> , 32, 186-191	14
1101	Management of myelodysplastic syndromes after failure of response to hypomethylating agents. <b>2019</b> , 10, 2040620719847059	16
1100	Evolutionary trajectory of leukemic clones and its clinical implications. <b>2019</b> , 104, 872-880	13
1099	National Cancer Institute (NCI) state of the science: Targeted radiosensitizers in colorectal cancer. <b>2019</b> , 125, 2732-2746	9
1098	Downregulation of CD73 associates with T cell exhaustion in AML patients. <b>2019</b> , 12, 40	12
1097	A Phase I/II Trial of MEC (Mitoxantrone, Etoposide, Cytarabine) in Combination with Ixazomib for Relapsed Refractory Acute Myeloid Leukemia. <b>2019</b> , 25, 4231-4237	19
1096	Leveraging Single-Cell RNA Sequencing Experiments to Model Intratumor Heterogeneity. <b>2019</b> , 3, 1-10	12

1095	Epidemiology of acute myeloid leukemia: Recent progress and enduring challenges. <b>2019</b> , 36, 70-87	212
1094	FLT3 Inhibitor Maintenance After Allogeneic Transplantation: Is a Placebo-Controlled, Randomized Trial Ethical?. <b>2019</b> , 37, 1604-1607	19
1093	The assessment of minimal residual disease versus that of somatic mutations for predicting the outcome of acute myeloid leukemia patients. <b>2019</b> , 19, 83	3
1092	New Targeted Agents in Acute Myeloid Leukemia: New Hope on the Rise. <b>2019</b> , 20,	54
1091	Targeting ADP-ribosylation by PARP inhibitors in acute myeloid leukaemia and related disorders. <b>2019</b> , 167, 133-148	14
1090	Challenges in the diagnosis and treatment of secondary acute myeloid leukemia. <b>2019</b> , 138, 6-13	8
1089	Emerging Therapies for Acute Myelogenous Leukemia Patients Targeting Apoptosis and Mitochondrial Metabolism. <b>2019</b> , 11,	16
1088	Choosing induction chemotherapy in therapy-related acute myeloid leukemia. <b>2019</b> , 32, 89-97	2
1087	New drugs creating new challenges in acute myeloid leukemia. <b>2019</b> , 58, 903-914	27
1086	[Kinase inhibitors in oncology : What is new?]. <b>2019</b> , 60, 540-544	
1085	Properties of FDA-approved small molecule protein kinase inhibitors. <b>2019</b> , 144, 19-50	247
1084	Treatment of myelodysplastic syndrome in the era of next-generation sequencing. <b>2019</b> , 286, 41-62	8
1083	Ushering in the next generation of precision trials for pediatric cancer. <b>2019</b> , 363, 1175-1181	27
1082	Genetic alterations of triple negative breast cancer (TNBC) in women from Northeastern Mexico. <b>2019</b> , 17, 3581-3588	6
1081	Quizartinib (AC220): a promising option for acute myeloid leukemia. <b>2019</b> , 13, 1117-1125	19
1080	Personalizing therapy for older adults with acute myeloid leukemia: Role of geriatric assessment and genetic profiling. <b>2019</b> , 75, 52-61	16
1079	Akute myeloische Leukämie bei Erwachsenen – Ein Update zu Diagnostik, Risikoklassifikation und Therapie. <b>2019</b> , 40, 37-42	
1078	Phase II clinical trial of pazopanib in patients with acute myeloid leukemia (AML), relapsed or refractory or at initial diagnosis without an intensive treatment option (PazoAML). <b>2019</b> , 98, 1393-1401	6

1077	Next-Generation Sequencing of Tissue and Circulating Tumor DNA: The UC San Diego Moores Center for Personalized Cancer Therapy Experience with Breast Malignancies. <b>2019</b> , 18, 1001-1011	24
1076	Induction therapy in acute myeloid leukemia: Is it time to put aside standard 3+7?. <b>2019</b> , 37, 558-563	7
1075	Optimizing survival outcomes with post-remission therapy in acute myeloid leukemia. <b>2019</b> , 94, 803-811	23
1074	Partnering with PARP inhibitors in acute myeloid leukemia with FLT3-ITD. <b>2019</b> , 454, 171-178	6
1073	Sorafenib improves survival of -mutated acute myeloid leukemia in relapse after allogeneic stem cell transplantation: a report of the EBMT Acute Leukemia Working Party. <b>2019</b> , 104, e398-e401	32
1072	Next Generation Sequencing in AML-On the Way to Becoming a New Standard for Treatment Initiation and/or Modulation?. <b>2019</b> , 11,	28
1071	FLT3 Inhibitors as Sensitizing Agents for Cancer Chemotherapy. <b>2019</b> , 67-88	0
1070	Can allogeneic hematopoietic cell transplant cure therapy-related acute leukemia?. <b>2019</b> , 32, 104-113	3
1069	Comparing the epidemiology, clinical characteristics and prognostic factors of acute myeloid leukemia with and without acute promyelocytic leukemia. <b>2019</b> , 40, 651-660	7
1068	Epigenetic therapy combinations in acute myeloid leukemia: what are the options?. <b>2019</b> , 10, 2040620718816698	9
1067	Complex karyotype in de novo acute myeloid leukemia: typical and atypical subtypes differ molecularly and clinically. <b>2019</b> , 33, 1620-1634	30
1066	Altered NFE2 activity predisposes to leukemic transformation and myelosarcoma with AML-specific aberrations. <b>2019</b> , 133, 1766-1777	10
1065	IDH2 inhibition: another piece to the puzzle. <b>2019</b> , 133, 625-626	1
1064	Identifying leukemia-associated immunophenotype-based individualized minimal residual disease in acute myeloid leukemia and its prognostic significance. <b>2019</b> , 94, 528-538	11
1063	Randomized phase-II trial evaluating induction therapy with idarubicin and etoposide plus sequential or concurrent azacitidine and maintenance therapy with azacitidine. <b>2019</b> , 33, 1923-1933	5
1062	Outpatient induction and consolidation care strategies in acute myeloid leukemia. <b>2019</b> , 26, 65-70	10
1061	Progress in the problem of relapsed or refractory acute myeloid leukemia. <b>2019</b> , 26, 88-95	13
1060	Shifting paradigms in the treatment of older adults with AML. <b>2019</b> , 56, 110-117	9

1059	Emerging treatment paradigms with FLT3 inhibitors in acute myeloid leukemia. <b>2019</b> , 10, 2040620719827310	63
1058	Therapy of acute myeloid leukemia: therapeutic targeting of tyrosine kinases. <b>2019</b> , 28, 337-349	9
1057	HSP90 inhibition depletes DNA repair proteins to sensitize acute myelogenous leukemia to nucleoside analog chemotherapeutics. <b>2019</b> , 60, 2308-2311	4
1056	Midostaurin for the management of FLT3-mutated acute myeloid leukemia and advanced systemic mastocytosis. <b>2019</b> , 76, 268-274	2
1055	[Diagnosis and treatment of acute myeloid leukemia : The updated 2018 Onkopedia Guideline]. <b>2019</b> , 60, 257-272	2
1054	Staging and general management. <b>2019</b> ,	
1053	Articles Title ch_5. <b>2019</b> ,	
1052	Randomized trial comparing standard vs sequential high-dose chemotherapy for inducing early CR in adult AML. <b>2019</b> , 3, 1103-1117	11
1051	DNA damage on the DOCK in FLT3-ITD-driven acute myeloid leukemia. <b>2019</b> , 104, 2330-2332	
1050	Selective targeting of NAMPT by KPT-9274 in acute myeloid leukemia. <b>2019</b> , 3, 242-255	23
1049	Evaluation of event-free survival as a robust end point in untreated acute myeloid leukemia (Alliance A151614). <b>2019</b> , 3, 1714-1721	6
1048	Hematopoietic cytokines mediate resistance to targeted therapy in FLT3-ITD acute myeloid leukemia. <b>2019</b> , 3, 1061-1072	21
1047	Patients with FLT3-mutant AML needed to enroll on FLT3-targeted therapeutic clinical trials. <b>2019</b> , 3, 4055-4064	1
1046	Do next-generation sequencing results drive diagnostic and therapeutic decisions in MDS?. <b>2019</b> , 3, 3454-3460	2
1045	Erythroid differentiation of myeloblast induced by gilteritinib in relapsed FLT3-ITD-positive acute myeloid leukemia. <b>2019</b> , 3, 3709-3712	9
1044	Complex karyotype AML displays G2/M signature and hypersensitivity to PLK1 inhibition. <b>2019</b> , 3, 552-563	14
1043	European Medicines Agency review of midostaurin (Rydapt) for the treatment of adult patients with acute myeloid leukaemia and systemic mastocytosis. <b>2019</b> , 4,	9
1042	Beyond midostaurin: Which are the most promising FLT3 inhibitors in AML?. <b>2019</b> , 32, 101103	6

1041	Quizartinib in the treatment of FLT3-internal-tandem duplication-positive acute myeloid leukemia. <b>2019</b> , 15, 3885-3894	2
1040	Midostaurin: Nursing Perspectives on Managing Treatment and Adverse Events in Patients With FLT3 Mutation-Positive Acute Myeloid Leukemia and Advanced Systemic Mastocytosis. <b>2019</b> , 23, 599-608	1
1039	Reflections on and future of hematologic malignancies research in the Veterans Health Administration. <b>2019</b> , 46, 346-350	0
1038	Gab2 is Essential for Transformation by FLT3-ITD in Acute Myeloid Leukemia. <b>2019</b> , 1	
1037	Expression of myeloid Src-family kinases is associated with poor prognosis in AML and influences Flt3-ITD kinase inhibitor acquired resistance. <b>2019</b> , 14, e0225887	9
1036	Cost-Effectiveness Of Midostaurin In The Treatment Of Acute Myeloid Leukemia With The FLT3 Mutation In Spain. <b>2019</b> , 11, 683-694	2
1035	The Important Role of Immunotherapies in Acute Myeloid Leukemia. <b>2019</b> , 8,	4
1034	Cancer biomarkers for targeted therapy. <b>2019</b> , 7, 25	38
1033	Novel Therapies in Acute Myeloid Leukemia. <b>2019</b> , 35, 150955	6
1032	Advances in Genomic Profiling and Risk Stratification in Acute Myeloid Leukemia. <b>2019</b> , 35, 150957	3
1031	Shared Decision-making in Acute Myeloid Leukemia. <b>2019</b> , 35, 150958	6
1030	Clinical value of new drugs in acute myeloid leukemia.. <b>2019</b> , 3,	
1029	Neoantigens in Hematological Malignancies-Ultimate Targets for Immunotherapy?. <b>2019</b> , 10, 3004	13
1028	A Case of Fusion Mutation in Adult Acute Lymphoblastic Leukemia (ALL), a Known Activating Mutation Reported in ALL. <b>2019</b> , 9, 1303	1
1027	Application of Genomics to Clinical Practice in Haematological Malignancy. <b>2019</b> , 7, 236-252	
1026	Nanopore Targeted Sequencing for Rapid Gene Mutations Detection in Acute Myeloid Leukemia. <b>2019</b> , 10,	14
1025	Azole antifungals and new targeted therapies for hematological malignancy. <b>2019</b> , 32, 538-545	28
1024	The Impact of the Cellular Origin in Acute Myeloid Leukemia: Learning From Mouse Models. <b>2019</b> , 3, e152	7

1023	Gab2 is Essential for Transformation by FLT3-ITD in Acute Myeloid Leukemia. <b>2019</b> , 3, e184	1
1022	Shifting therapeutic paradigms in induction and consolidation for older adults with acute myeloid leukemia. <b>2019</b> , 26, 51-57	4
1021	Which patients with acute myeloid leukemia in CR1 can be spared an allogeneic transplant?. <b>2019</b> , 26, 58-64	4
1020	MEK inhibition enhances the response to tyrosine kinase inhibitors in acute myeloid leukemia. <b>2019</b> , 9, 18630	7
1019	Core Binding Factor Leukemia: Chromatin Remodeling Moves Towards Oncogenic Transcription. <b>2019</b> , 11,	6
1018	Posttransplant maintenance therapy for acute leukemias. <b>2019</b> , 26, 96-111	2
1017	Transcriptional Silencing of MCL-1 Through Cyclin-Dependent Kinase Inhibition in Acute Myeloid Leukemia. <b>2019</b> , 9, 1205	17
1016	What's new in consolidation therapy in AML?. <b>2019</b> , 56, 96-101	8
1015	Maintenance therapy in acute myeloid leukemia: What is the future?. <b>2019</b> , 56, 102-109	8
1014	Clinical implications of molecular markers in acute myeloid leukemia. <b>2019</b> , 102, 20-35	26
1013	A phase 1/2, open-label, dose-escalation study of midostaurin in children with relapsed or refractory acute leukaemia. <b>2019</b> , 185, 623-627	13
1012	Comprehensive genetic diagnosis of acute myeloid leukemia by next-generation sequencing. <b>2019</b> , 104, 277-287	20
1011	Classes of ITD Predict Outcomes in AML Patients Treated with FLT3 Inhibitors. <b>2019</b> , 25, 573-583	7
1010	Treatment patterns and healthcare resource utilization in patients with FLT3-mutated and wild-type acute myeloid leukemia: A medical chart study. <b>2019</b> , 102, 341-350	9
1009	Comprehensive Genomic Profiling Reveals Diverse but Actionable Molecular Portfolios across Hematologic Malignancies: Implications for Next Generation Clinical Trials. <b>2018</b> , 11,	16
1008	Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with -ITD. <b>2019</b> , 133, 840-851	141
1007	Discontinuation of sorafenib can lead to the emergence of FLT3-ITD-positive acute myeloid leukemia. <b>2019</b> , 25, 2010-2015	0
1006	Advances in patient care through increasingly individualized therapy. <b>2019</b> , 16, 73-74	19

1005	Cost Effectiveness of Midostaurin in the Treatment of Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia in the United States. <b>2019</b> , 37, 239-253	7
1004	Whole exome sequencing in the diagnostic workup of patients with a bleeding diathesis. <b>2019</b> , 25, 127-135	10
1003	Cladribine in the remission induction of adult acute myeloid leukemia: where do we stand?. <b>2019</b> , 98, 561-579	4
1002	Acute Leukemia. <b>2019</b> , 343-354	
1001	Targeting FLT3 mutations in AML: review of current knowledge and evidence. <b>2019</b> , 33, 299-312	324
1000	Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms. <b>2019</b> , 10, 244	63
999	Midostaurin potentiates rituximab antitumor activity in Burkitt's lymphoma by inducing apoptosis. <b>2018</b> , 10, 8	5
998	Computational modeling of early T-cell precursor acute lymphoblastic leukemia (ETP-ALL) to identify personalized therapy using genomics. <b>2019</b> , 78, 3-11	9
997	Are we witnessing the start of a therapeutic revolution in acute myeloid leukemia?. <b>2019</b> , 60, 1354-1369	19
996	The FLT3 inhibitor midostaurin selectively resensitizes ABCB1-overexpressing multidrug-resistant cancer cells to conventional chemotherapeutic agents. <b>2019</b> , 445, 34-44	20
995	Azacitidine maintenance after intensive chemotherapy improves DFS in older AML patients. <b>2019</b> , 133, 1457-1464	79
994	Relapse of Acute Myeloid Leukemia after Allogeneic Stem Cell Transplantation: Prevention, Detection, and Treatment. <b>2019</b> , 20,	56
993	Expedited Analysis and Reporting of Multiple Mutations that Modify Medical Management of Myeloid Malignancies: It's About (Turnaround) Time!. <b>2019</b> , 21, 13-15	
992	Risks and benefits in a personalized application of allogeneic transplantation in patients with AML in first CR. <b>2019</b> , 56, 164-170	8
991	Metabolic underpinnings of leukemia pathology and treatment. <b>2019</b> , 2, e1139	3
990	Validation of the 2017 European LeukemiaNet classification for acute myeloid leukemia with NPM1 and FLT3-internal tandem duplication genotypes. <b>2019</b> , 125, 1091-1100	30
989	Neutropenic enterocolitis in patients with FLT3 mutated acute myeloid leukemia undergoing induction chemotherapy with midostaurin. <b>2019</b> , 109, 351-355	3
988	Management of primary refractory acute myeloid leukemia in the era of targeted therapies. <b>2019</b> , 60, 583-597	3

987	Midostaurin administration in two hemodialysis patients. <b>2019</b> , 25, 1285-1288	0
986	FLT3 inhibitors in acute myeloid leukemia: Current and future. <b>2019</b> , 25, 163-171	8
985	Isavuconazole therapy in an FLT3 mutated acute myeloid leukemia patient receiving midostaurin: A case report. <b>2019</b> , 25, 987-989	5
984	Allogeneic hematopoietic cell transplantation improves outcome of adults with t(6;9) acute myeloid leukemia: results from an international collaborative study. <b>2020</b> , 105, 161-169	8
983	Azacytidine in Newly Diagnosed FLT3-ITD-Positive Acute Myeloid Leukemia Presenting with Pneumonia: A Case Series. <b>2020</b> , 36, 377-380	
982	CPX-351 (vyxeos) in AML. <b>2020</b> , 61, 288-297	29
981	Impact of FLT3-ITD allele ratio and ITD length on therapeutic outcome in cytogenetically normal AML patients without NPM1 mutation. <b>2020</b> , 55, 740-748	19
980	Necrotizing Hemorrhagic Gastritis following Acute Myeloid Leukemia Induction with Midostaurin: An Unexpected Complication. <b>2020</b> , 143, 65-68	3
979	Acute Myeloid Leukemia: A New Era of Therapies, a New Wave of Toxicities?. <b>2020</b> , 143, 5-6	1
978	Hybridization capture-based next generation sequencing reliably detects FLT3 mutations and classifies FLT3-internal tandem duplication allelic ratio in acute myeloid leukemia: a comparative study to standard fragment analysis. <b>2020</b> , 33, 334-343	6
977	Targeting Immunophenotypic Markers on Leukemic Stem Cells: How Lessons from Current Approaches and Advances in the Leukemia Stem Cell (LSC) Model Can Inform Better Strategies for Treating Acute Myeloid Leukemia (AML). <b>2020</b> , 10,	8
976	Diverse pathogenetic roles of SOX genes in acute myeloid leukaemia and their therapeutic implications. <b>2020</b> , 67, 24-29	1
975	Sorafenib and omacetaxine mepesuccinate as a safe and effective treatment for acute myeloid leukemia carrying internal tandem duplication of Fms-like tyrosine kinase 3. <b>2020</b> , 126, 344-353	7
974	The golden age for patients in their golden years: The progressive upheaval of age and the treatment of newly-diagnosed acute myeloid leukemia. <b>2020</b> , 40, 100639	11
973	A Phase II Study of Midostaurin and 5-Azacitidine for Untreated Elderly and Unfit Patients With FLT3 Wild-type Acute Myelogenous Leukemia. <b>2020</b> , 20, 226-233.e1	7
972	The evolving role of next generation sequencing in myelodysplastic syndromes. <b>2020</b> , 188, 224-239	7
971	Therapeutic Choice in Older Patients with Acute Myeloid Leukemia: A Matter of Fitness. <b>2020</b> , 12,	17
970	FLT3 inhibitors in acute myeloid leukemia: ten frequently asked questions. <b>2020</b> , 34, 682-696	61



969	Is outcome of older people with acute myeloid leukemia improving with new therapeutic approaches and stem cell transplantation?. <b>2020</b> , 13, 99-108	0
968	Recent drug approvals for newly diagnosed acute myeloid leukemia: gifts or a Trojan horse?. <b>2020</b> , 34, 671-681	32
967	A new regulatory mechanism of protein phosphatase 2A activity via SET in acute myeloid leukemia. <b>2020</b> , 10, 3	10
966	The minimal that kills: Why defining and targeting measurable residual disease is the "Sine Qua Non" for further progress in management of acute myeloid leukemia. <b>2020</b> , 43, 100650	8
965	Treatment Strategies for Therapy-related Acute Myeloid Leukemia. <b>2020</b> , 20, 147-155	3
964	Pediatric acute myeloid leukemia: updates on biology, risk stratification, and therapy. <b>2020</b> , 32, 57-66	31
963	Pregnancy exposure to midostaurin in the first trimester. <b>2020</b> , 99, 355-356	1
962	The leukaemia stem cell: similarities, differences and clinical prospects in CML and AML. <b>2020</b> , 20, 158-173	74
961	FLT3 mutations in acute myeloid leukemia: Therapeutic paradigm beyond inhibitor development. <b>2020</b> , 111, 312-322	45
960	The face of remission induction. <b>2020</b> , 188, 101-115	2
959	Twenty five years of UK trials in acute myeloid leukaemia: what have we learned?. <b>2020</b> , 188, 86-100	9
958	Clinical Utility of Next-Generation Sequencing in Acute Myeloid Leukemia. <b>2020</b> , 24, 1-13	11
957	The role of allogeneic stem cell transplantation in the management of acute myeloid leukaemia: a triumph of hope and experience. <b>2020</b> , 188, 129-146	29
956	Single-Arm Phase II Trials of Combination Therapies: A Review of the CTEP Experience 2008-2017. <b>2020</b> , 112, 128-135	1
955	Treatment practice and outcomes in mutant acute myeloid leukemia in the pre-midostaurin era: a real-world experience from Australian tertiary hospitals. <b>2020</b> , 61, 848-854	0
954	Mastocytosis. <b>2020</b> ,	0
953	Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia With Genomic Evidence of Residual Disease. <b>2020</b> , 38, 1273-1283	131
952	AML through the prism of molecular genetics. <b>2020</b> , 188, 49-62	7

951	Novel Approaches to Target Mutant FLT3 Leukaemia. <b>2020</b> , 12,	2
950	Access to Therapy for Acute Myeloid Leukemia in the Developing World: Barriers and Solutions. <b>2020</b> , 22, 125	7
949	Characterization and mitigation of fragmentation enzyme-induced dual stranded artifacts. <b>2020</b> , 2, lqaa070	0
948	Advancing leukemia diagnostics: Role of Next Generation Sequencing (NGS) in acute myeloid leukemia. <b>2020</b> , 12, 8957	3
947	A precision medicine approach to management of acute myeloid leukemia in older adults. <b>2020</b> , 32, 650-655	1
946	Synergistic effect of BCL2 and FLT3 co-inhibition in acute myeloid leukemia. <b>2020</b> , 13, 139	12
945	Sunitinib in Patients with Metastatic Colorectal Cancer (mCRC) with FLT-3 Amplification: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. <b>2020</b> , 15, 743-750	9
944	Hyperleukocytosis and Leukostasis in Acute Myeloid Leukemia: Can a Better Understanding of the Underlying Molecular Pathophysiology Lead to Novel Treatments?. <b>2020</b> , 9,	7
943	Minimal Residual Disease in Acute Myeloid Leukemia. <b>2020</b> , 6, 1899-1900	3
942	Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML. <b>2020</b> , 13, 132	6
941	CPX-351 treatment in secondary acute myeloblastic leukemia is effective and improves the feasibility of allogeneic stem cell transplantation: results of the Italian compassionate use program. <b>2020</b> , 10, 96	9
940	Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: a subanalysis from the RATIFY trial. <b>2020</b> , 4, 4945-4954	13
939	Profiling Mutations in Mexican Acute Myeloid Leukemia Pediatric Patients: Impact on Overall Survival. <b>2020</b> , 8, 586	3
938	Analysis of estimated clinical benefit of newly approved drugs for US patients with acute myeloid leukemia. <b>2020</b> , 96, 106420	3
937	Overexpression of annexin A5 might guide the gemtuzumab ozogamicin treatment choice in patients with pediatric acute myeloid leukemia. <b>2020</b> , 12, 1758835920927635	1
936	Glasdegib as maintenance therapy for patients with AML and MDS patients at high risk for postallogeneic stem cell transplant relapse. <b>2020</b> , 4, 3102-3108	11
935	Targeted Informatics for Optimal Detection, Characterization, and Quantification of FLT3 Internal Tandem Duplications Across Multiple Next-Generation Sequencing Platforms. <b>2020</b> , 22, 1162-1178	6
934	Allogeneic stem cell transplantation for high-risk acute leukemia and maintenance therapy: no time to waste. <b>2020</b> , 4, 3200-3204	2

933	Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With -Internal Tandem Duplication Mutation (SORMAIN). <b>2020</b> , 38, 2993-3002	122
932	Drug-drug interactions of newly approved small molecule inhibitors for acute myeloid leukemia. <b>2020</b> , 99, 1989-2007	11
931	Should we screen patients with hematologic malignancies for COVID-19?. <b>2020</b> , 38, 648-653	
930	After Treatment Decrease of Bone Marrow Tregs and Outcome in Younger Patients with Newly Diagnosed Acute Myeloid Leukemia. <b>2020</b> , 2020, 2134647	1
929	Molecular Mechanisms of Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia: Ongoing Challenges and Future Treatments. <b>2020</b> , 9,	13
928	Therapeutic targeting of FLT3 and associated drug resistance in acute myeloid leukemia. <b>2020</b> , 13, 155	7
927	Advances of Nanoparticles for Leukemia Treatment. <b>2020</b> , 6, 6478-6489	4
926	Pharmacologic Therapies to Prevent Relapse of Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation. <b>2020</b> , 10, 596134	8
925	Emerging treatment options for patients with high-risk myelodysplastic syndrome. <b>2020</b> , 11, 2040620720955086	
924	Current and emerging molecular and epigenetic disease entities in acute myeloid leukemia and a critical assessment of their therapeutic modalities. <b>2020</b> ,	2
923	Mutational screening of RTK-BRAF genes in de novo adult acute myeloid leukemia. <b>2020</b> , 21, 100904	
922	Targeted RNA-Sequencing Enables Detection of Relevant Translocations and Single Nucleotide Variants and Provides a Method for Classification of Hematological Malignancies-RANKING. <b>2020</b> , 66, 1521-1530	2
921	Management of toxicities associated with targeted therapies for acute myeloid leukemia: when to push through and when to stop. <b>2020</b> , 2020, 57-66	2
920	FLT3 inhibitors in acute myeloid leukaemia: assessment of clinical effectiveness, adverse events and future research-a systematic review and meta-analysis. <b>2020</b> , 9, 285	8
919	Cell cycle inhibitors for the treatment of acute myeloid leukemia: a review of phase 2 & 3 clinical trials. <b>2020</b> , 25, 491-499	1
918	Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia of the Elderly: Review of Literature and New Perspectives. <b>2020</b> , 12, e2020081	4
917	Treating acute myeloid leukemia in the modern era: A primer. <b>2020</b> , 126, 4668-4677	12
916	The successful use of inhibitors in -positive mixed phenotype acute leukemia. <b>2020</b> , 61, 3275-3277	3

915	Mechanistic insights and potential therapeutic approaches for NUP98-rearranged hematologic malignancies. <b>2020</b> , 136, 2275-2289	21
914	Repurposing of Kinase Inhibitors for Treatment of COVID-19. <b>2020</b> , 37, 167	61
913	Maintenance after allogeneic HSCT in acute myeloid leukaemia. <b>2020</b> , 21, 1130-1132	2
912	Genomic landscape in acute myeloid leukemia and its implications in risk classification and targeted therapies. <b>2020</b> , 27, 81	18
911	Management of Acute Myeloid Leukemia (AML) in Older Patients. <b>2020</b> , 22, 103	3
910	Mechanisms Underlying Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia. <b>2020</b> , 8,	12
909	Cutting Edge Molecular Therapy for Acute Myeloid Leukemia. <b>2020</b> , 21,	4
908	BCL-2 Inhibitor and Conventional Chemotherapy Combinations for Acute Myeloid Leukemia: Shifting From the Unfit to the Fit Patient With AML. <b>2020</b> , 38, 3461-3464	1
907	MED13L integrates Mediator-regulated epigenetic control into lung cancer radiosensitivity. <b>2020</b> , 10, 9378-9394	11
906	Reduced-intensity versus Myeloablative Conditioning Regimens for Younger Adults with Acute Myeloid Leukemia and Myelodysplastic Syndrome: A systematic review and meta-analysis. <b>2020</b> , 11, 5223-5235 <sup>3</sup>	
905	Real-World Outcomes of Patients with Refractory or Relapsed -ITD Acute Myeloid Leukemia: A Toulouse-Bordeaux DATAML Registry Study. <b>2020</b> , 12,	3
904	Survivorship in AML - a landmark analysis on the outcomes of acute myelogenous leukemia patients after maintaining complete remission for at least 3 years. <b>2020</b> , 61, 3120-3127	5
903	Quizartinib for the treatment of acute myeloid leukemia. <b>2020</b> , 21, 2077-2090	7
902	Small-molecule active pharmaceutical ingredients of approved cancer therapeutics inhibit human aspartate/asparagine- $\beta$ -hydroxylase. <b>2020</b> , 28, 115675	5
901	Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial. <b>2020</b> , 26, 1852-1858	32
900	Ex vivo cultures and drug testing of primary acute myeloid leukemia samples: Current techniques and implications for experimental design and outcome. <b>2020</b> , 53, 100730	5
899	Long-term outcomes in patients with AML achieving first complete remission: confronting the double-hit of survivorship. <b>2020</b> , 61, 3035-3037	
898	New directions for emerging therapies in acute myeloid leukemia: the next chapter. <b>2020</b> , 10, 107	36

897	Diagnosis and Treatment of Patients With Acute Myeloid Leukemia With Myelodysplasia-Related Changes (AML-MRC). <b>2020</b> , 154, 731-741	4
896	Management of higher risk myelodysplastic syndromes after hypomethylating agents failure: are we about to exit the black hole?. <b>2020</b> , 13, 1131-1142	3
895	Precision medicine in acute myeloid leukemia: where are we now and what does the future hold?. <b>2020</b> , 13, 1057-1065	1
894	Erlotinib is effective against FLT3-ITD mutant AML and helps to overcome intratumoral heterogeneity via targeting FLT3 and Lyn. <b>2020</b> , 34, 10182-10190	1
893	Natural and Semisynthetic Chalcones as Dual FLT3 and Microtubule Polymerization Inhibitors. <b>2020</b> , 83, 3111-3121	9
892	Pyridoxine induces monocyte-macrophages death as specific treatment of acute myeloid leukemia. <b>2020</b> , 492, 96-105	3
891	Diagnostic and molecular testing patterns in patients with newly diagnosed acute myeloid leukemia in the Connect MDS/AML Disease Registry. <b>2020</b> , 1, 58-68	1
890	Experiences with Next-Generation Sequencing in Relapsed Acute Myeloid Leukemia: A Patient Case Series. <b>2020</b> , 12, e2020068	0
889	Characterization of FLT3-ITD acute myeloid leukemia: molecular profiling of leukemic precursor cells. <b>2020</b> , 10, 85	4
888	Uncommon cytogenetic abnormalities identifying high-risk acute myeloid leukemia in children. <b>2020</b> , 16, 2747-2762	1
887	Withanolide Metabolites Inhibit PI3K/AKT and MAPK Pro-Survival Pathways and Induce Apoptosis in Acute Myeloid Leukemia Cells. <b>2020</b> , 8,	4
886	Ibrutinib added to 10-day decitabine for older patients with AML and higher risk MDS. <b>2020</b> , 4, 4267-4277	4
885	High Throughput Molecular Characterization of Normal Karyotype Acute Myeloid Leukemia in the Context of the Prospective Trial 02/06 of the Northern Italy Leukemia Group (NILG). <b>2020</b> , 12,	2
884	Genomic Strategies for Personalized Cancer Therapy. <b>2020</b> , 1-60	
883	Chlorpromazine eliminates acute myeloid leukemia cells by perturbing subcellular localization of FLT3-ITD and KIT-D816V. <b>2020</b> , 11, 4147	7
882	Updated safety of midostaurin plus chemotherapy in newly diagnosed mutation-positive acute myeloid leukemia: the RADIUS-X expanded access program. <b>2020</b> , 61, 3146-3153	4
881	Deletions in BCP-ALL result in a TAD more FLT3. <b>2020</b> , 136, 919-920	1
880	Acute myeloid leukemia: 2021 update on risk-stratification and management. <b>2020</b> , 95, 1368-1398	25

879	Zebrafish models of acute leukemias: Current models and future directions. <b>2021</b> , 10, e400		0
878	Upfront Treatment of FLT3-Mutated AML: A Look Back at the RATIFY Trial and Beyond. <b>2020</b> , 10, 562219		0
877	Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission. <i>New England Journal of Medicine</i> , <b>2020</b> , 383, 2526-2537	59.2	100
876	Mutations in Acute Myeloid Leukemia: Key Concepts and Emerging Controversies. <b>2020</b> , 10, 612880		24
875	Acute Myeloid Leukemia: From Biology to Clinical Practices Through Development and Pre-Clinical Therapeutics. <b>2020</b> , 10, 599933		4
874	Activating JAK-mutations confer resistance to FLT3 kinase inhibitors in FLT3-ITD positive AML in vitro and in vivo. <b>2021</b> , 35, 2017-2029		10
873	Multilineage Dysplasia as Assessed by Immunophenotype in Acute Myeloid Leukemia: A Prognostic Tool in a Genetically Undefined Category. <b>2020</b> , 12,		1
872	Venetoclax-Based Combinations in Acute Myeloid Leukemia: Current Evidence and Future Directions. <b>2020</b> , 10, 562558		15
871	In response to "American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults". <b>2020</b> , 4, 5431-5432		1
870	High expression of the stem cell marker GPR56 at diagnosis identifies acute myeloid leukemia patients at higher relapse risk after allogeneic stem cell transplantation in context with the CD34+/CD38- population. <b>2020</b> , 105, e507		5
869	Phosphotyrosine-based Phosphoproteomics for Target Identification and Drug Response Prediction in AML Cell Lines. <b>2020</b> , 19, 884-899		13
868	Chimeric antigen receptor therapy in hematological malignancies: antigenic targets and their clinical research progress. <b>2020</b> , 99, 1681-1699		4
867	Risk stratification using FLT3 and NPM1 in acute myeloid leukemia patients autografted in first complete remission. <b>2020</b> , 55, 2244-2253		1
866	Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AML. <b>2020</b> , 4, 1894-1905		62
865	Sequencing-Based Measurable Residual Disease Testing in Acute Myeloid Leukemia. <b>2020</b> , 8, 249		13
864	Antifungal and Oral Anticancer Therapy Drug Interactions. <b>2020</b> , 14, 130-140		0
863	Impact of numerical variation, allele burden, mutation length and co-occurring mutations on the efficacy of tyrosine kinase inhibitors in newly diagnosed FLT3- mutant acute myeloid leukemia. <b>2020</b> , 10, 48		10
862	ULK1 inhibition as a targeted therapeutic strategy for FLT3-ITD-mutated acute myeloid leukemia. <b>2020</b> , 39, 85		11

861	Considerations for Managing Patients With Hematologic Malignancy During the COVID-19 Pandemic: The Seattle Strategy. <b>2020</b> , 16, 571-578	17
860	Dasatinib response in acute myeloid leukemia is correlated with FLT3/ITD, PTPN11 mutations and a unique gene expression signature. <b>2020</b> , 105, 2795-2804	5
859	Molecular Landscape of Acute Myeloid Leukemia: Prognostic and Therapeutic Implications. <b>2020</b> , 22, 61	10
858	Acute myeloid leukemia transformed to a targetable disease. <b>2020</b> , 16, 961-972	5
857	Dasatinib overcomes stroma-based resistance to the FLT3 inhibitor quizartinib using multiple mechanisms. <b>2020</b> , 34, 2981-2991	2
856	FLT3 inhibitors added to induction therapy induce deeper remissions. <b>2020</b> , 135, 75-78	13
855	Additional gene mutations may refine the 2017 European LeukemiaNet classification in adult patients with de novo acute myeloid leukemia aged . <b>2020</b> , 34, 3215-3227	24
854	Genomics-guided pre-clinical development of cancer therapies.. <b>2020</b> , 1, 482-492	9
853	Allogeneic hematopoietic stem cell transplantation at the first remission for younger adults with FLT3-internal tandem duplication AML: The JALSG AML209-FLT3-SCT study. <b>2020</b> , 111, 2472-2481	1
852	Management of challenging myelofibrosis after JAK inhibitor failure and/or progression. <b>2020</b> , 42, 100716	6
851	Advances in targeted therapy for acute myeloid leukemia. <b>2020</b> , 8, 17	17
850	Novel therapeutic strategies for MLL-rearranged leukemias. <b>2020</b> , 1863, 194584	1
849	Novel Treatment Paradigms in Acute Myeloid Leukemia. <b>2020</b> , 108, 506-514	5
848	Overexpression of HOXA10 is associated with unfavorable prognosis of acute myeloid leukemia. <b>2020</b> , 20, 586	10
847	Diagnostic and Therapeutic Considerations for Extramedullary Leukemia. <b>2020</b> , 22, 75	8
846	The prognostic impact of FLT3-ITD, NPM1 and CEBPa in cytogenetically intermediate-risk AML after first relapse. <b>2020</b> , 112, 200-209	4
845	Does time from diagnosis to treatment affect the prognosis of patients with newly diagnosed acute myeloid leukemia?. <b>2020</b> , 136, 823-830	35
844	Treatment of Acute Myeloid Leukemia in the Era of Genomics-Achievements and Persisting Challenges. <b>2020</b> , 11, 480	10

843	Cotargeting of XPO1 Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Acute Myeloid Leukemia. <b>2020</b> , 12,	6
842	Identifying effective drug combinations for patients with acute myeloid leukemia. <b>2020</b> , 20, 591-601	3
841	Gilteritinib in the treatment of relapsed and refractory acute myeloid leukemia with a FLT3 mutation. <b>2020</b> , 11, 2040620720930614	6
840	Acute myeloid leukemia with NPM1 mutation and favorable European LeukemiaNet category: outcome after preemptive intervention based on measurable residual disease. <b>2020</b> , 191, 52-61	12
839	Antifungal prophylaxis and novel drugs in acute myeloid leukemia: the midostaurin and posaconazole dilemma. <b>2020</b> , 99, 1429-1440	16
838	Characterization of a Novel FLT3 BiTE Molecule for the Treatment of Acute Myeloid Leukemia. <b>2020</b> , 19, 1875-1888	13
837	The global burden and attributable risk factor analysis of acute myeloid leukemia in 195 countries and territories from 1990 to 2017: estimates based on the global burden of disease study 2017. <b>2020</b> , 13, 72	55
836	Successful treatment with gilteritinib for isolated extramedullary relapse of acute myeloid leukemia with FLT3-ITD mutation after allogeneic stem cell transplantation. <b>2020</b> , 112, 243-248	6
835	High incidence of mutations in follicular thyroid cancer: potential therapeutic target in patients with advanced disease stage. <b>2020</b> , 12, 1758835920907534	1
834	Follistatin is a novel therapeutic target and biomarker in FLT3/ITD acute myeloid leukemia. <b>2020</b> , 12, e10895	5
833	Different liposome patterns to detection of acute leukemia based on electrochemical cell sensor. <b>2020</b> , 1109, 122-129	3
832	Small molecules, big impact: 20 years of targeted therapy in oncology. <b>2020</b> , 395, 1078-1088	107
831	Low-intensity regimens standard-intensity induction strategies in acute myeloid leukemia. <b>2020</b> , 11, 2040620720913010	8
830	Requirement for LIM kinases in acute myeloid leukemia. <b>2020</b> , 34, 3173-3185	5
829	How Allogeneic Hematopoietic Stem Cell Transplantation has Evolved Over Time: 30-Years' Experience at a Single Institution. <b>2020</b> , 33, 116-123	
828	The Novel Phospholipid Mimetic KPC34 Is Highly Active Against Acute Myeloid Leukemia with Activated Protein Kinase C. <b>2020</b> , 13, 100780	
827	Treatment of Relapsed Acute Myeloid Leukemia. <b>2020</b> , 21, 66	39
826	The FLAMSA concept-past and future. <b>2020</b> , 99, 1979-1988	3



825	NPM1-mutated acute myeloid leukemia: from bench to bedside. <b>2020</b> , 136, 1707-1721	52
824	Novel agents targeting leukemia cells and immune microenvironment for prevention and treatment of relapse of acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation. <b>2020</b> , 10, 2125-2139	4
823	Nonclinical Safety Assessment of AMG 553, an Investigational Chimeric Antigen Receptor T-Cell Therapy for the Treatment of Acute Myeloid Leukemia. <b>2020</b> , 177, 94-107	2
822	Synergistic targeting of FLT3 mutations in AML via combined menin-MLL and FLT3 inhibition. <b>2020</b> , 136, 2442-2456	27
821	Combination treatment with CPX-351 and midostaurin in patients with secondary acute myeloid leukaemia that are FLT3 mutated: three cases and review of literature. <b>2020</b> , 190, 467-470	0
820	Venetoclax and hypomethylating agents in FLT3-mutated acute myeloid leukemia. <b>2020</b> , 95, 1193	13
819	STAT5-dependent regulation of CDC25A by miR-16 controls proliferation and differentiation in FLT3-ITD acute myeloid leukemia. <b>2020</b> , 10, 1906	2
818	Interrogation of molecular profiles can help in differentiating between MDS and AML with MDS-related changes. <b>2020</b> , 61, 1418-1427	6
817	Venetoclax in acute myeloid leukemia - current and future directions. <b>2020</b> , 61, 1313-1322	14
816	An evaluation of glasdegib for the treatment of acute myelogenous leukemia. <b>2020</b> , 21, 523-530	9
815	From Bench to Bedside and Beyond: Therapeutic Scenario in Acute Myeloid Leukemia. <b>2020</b> , 12,	7
814	The Time Has Come for Targeted Therapies for AML: Lights and Shadows. <b>2020</b> , 8, 13-32	11
813	Overcoming Resistance to FLT3 Inhibitors in the Treatment of -Mutated AML. <b>2020</b> , 21,	18
812	Driver mutations in acute myeloid leukemia. <b>2020</b> , 27, 49-57	16
811	Asperuloside exhibits a novel anti-leukemic activity by triggering ER stress-regulated apoptosis via targeting GRP78. <b>2020</b> , 125, 109819	8
810	A User's Guide to Novel Therapies for Acute Myeloid Leukemia. <b>2020</b> , 20, 277-288	14
809	AML: New Drugs but New Challenges. <b>2020</b> , 20, 341-350	9
808	Improved Post remission survival of non- favorable risk Acute Myelogenous Leukemia (AML) patients following initial remission induction therapy with FLAG+/-Idarubicin versus 3 + 7 (Anthracycline + Cytarabine). <b>2020</b> , 93, 106318	4

807	Hematopoietic stem cell transplantation for blood cancers in the era of precision medicine and immunotherapy. <b>2020</b> , 126, 1837-1855	11
806	Phospho-Profiling Linking Biology and Clinics in Pediatric Acute Myeloid Leukemia. <b>2020</b> , 4, e312	6
805	Advances in non-intensive chemotherapy treatment options for adults diagnosed with acute myeloid leukemia. <b>2020</b> , 91, 106339	8
804	Tyrosine kinase inhibitors for acute myeloid leukemia: A step toward disease control?. <b>2020</b> , 44, 100675	11
803	New and Emerging Targeted Therapies for Pediatric Acute Myeloid Leukemia (AML). <b>2020</b> , 7,	10
802	Older adults in hematologic malignancy trials: Representation, barriers to participation and strategies for addressing underrepresentation. <b>2020</b> , 43, 100670	6
801	Stromal cell protein kinase C-inhibition enhances chemosensitivity in B cell malignancies and overcomes drug resistance. <b>2020</b> , 12,	10
800	Effects of the multi-kinase inhibitor midostaurin in combination with chemotherapy in models of acute myeloid leukaemia. <b>2020</b> , 24, 2968-2980	9
799	Targeted therapy in acute myeloid leukemia: current status and new insights from a proteomic perspective. <b>2020</b> , 17, 1-10	9
798	The combination of FLT3 and SYK kinase inhibitors is toxic to leukaemia cells with CBL mutations. <b>2020</b> , 24, 2145-2156	1
797	E2F4 functions as a tumour suppressor in acute myeloid leukaemia via inhibition of the MAPK signalling pathway by binding to EZH2. <b>2020</b> , 24, 2157-2168	10
796	Profile of Quizartinib for the Treatment of Adult Patients with Relapsed/Refractory FLT3-ITD-Positive Acute Myeloid Leukemia: Evidence to Date. <b>2020</b> , 12, 151-163	11
795	Unique case of ANCA-negative pauci-immune necrotizing glomerulonephritis with diffuse alveolar hemorrhage, potentially associated with midostaurin. <b>2020</b> , 9, 147-151	3
794	Preclinical efficacy for a novel tyrosine kinase inhibitor, ArQule 531 against acute myeloid leukemia. <b>2020</b> , 13, 8	11
793	CCL5 mediates target-kinase independent resistance to FLT3 inhibitors in FLT3-ITD-positive AML. <b>2020</b> , 14, 779-794	7
792	Cost-effectiveness of midostaurin in the treatment of newly diagnosed FLT3-mutated acute myeloid leukemia in France. <b>2020</b> , 21, 543-555	5
791	The genomics of acute myeloid leukemia in children. <b>2020</b> , 39, 189-209	8
790	Advances in the Treatment of Acute Myeloid Leukemia: New Drugs and New Challenges. <b>2020</b> , 10, 506-525	96

789	Gilteritinib: An FMS-like tyrosine kinase 3/AXL tyrosine kinase inhibitor for the treatment of relapsed or refractory acute myeloid leukemia patients. <b>2020</b> , 26, 1200-1212	3
788	The sensitivity of the -ITD detection method is an important consideration when diagnosing acute myeloid leukemia. <b>2020</b> , 13, 100198	4
787	Successful Treatment of Early Relapsed High-Risk AML After Allogeneic Hematopoietic Stem Cell Transplantation With Biomodulatory Therapy. <b>2020</b> , 10, 443	1
786	How we treat older patients with acute myeloid leukaemia. <b>2020</b> , 191, 682-691	2
785	Isavuconazole Therapy of Disseminated and Encephalic Infection in an Acute Myeloid Leukemia Patient Treated with Midostaurin. <b>2020</b> , 12, e2020026	4
784	The prognostic impact of FLT3-ITD and NPM1 mutation in adult AML is age-dependent in the population-based setting. <b>2020</b> , 4, 1094-1101	26
783	Outcome of Relapsed or Refractory -Mutated Acute Myeloid Leukemia Before Second-Generation FLT3 Tyrosine Kinase Inhibitors: A Toulouse-Bordeaux DATAML Registry Study. <b>2020</b> , 12,	4
782	Acute myeloid leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <b>2020</b> , 31, 697-712	75
781	Selection of initial therapy for newly-diagnosed adult acute myeloid leukemia: Limitations of predictive models. <b>2020</b> , 44, 100679	12
780	Chiral Analogues of PFI-1 as BET Inhibitors and Their Functional Role in Myeloid Malignancies. <b>2020</b> , 11, 1928-1934	16
779	Validation and refinement of the revised 2017 European LeukemiaNet genetic risk stratification of acute myeloid leukemia. <b>2020</b> , 34, 3161-3172	57
778	EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for haematological malignancies. <b>2020</b> , 5,	5
777	The PI3K-Akt-mTOR Signaling Pathway in Human Acute Myeloid Leukemia (AML) Cells. <b>2020</b> , 21,	55
776	Pre-transplant FLT3/ITD status predicts outcome in FLT3-mutated acute myeloid leukemia following allogeneic stem cell transplantation. <b>2020</b> , 99, 1845-1853	4
775	Mutations within the Activation Loop Domain of FLT3 in Two Pediatric Patients with Refractory Infant Acute Myeloid Leukemia. <b>2020</b> , 13, 266-270	0
774	High FLT3 Levels May Predict Sorafenib Benefit in Hepatocellular Carcinoma. <b>2020</b> , 26, 4302-4312	4
773	Targeting Apoptosis in Acute Myeloid Leukemia: Current Status and Future Directions of BCL-2 Inhibition with Venetoclax and Beyond. <b>2020</b> , 15, 147-162	12
772	Emerging pharmacotherapies for elderly acute myeloid leukemia patients. <b>2020</b> , 13, 619-643	3

771	Individualizing Treatment for Newly Diagnosed Acute Myeloid Leukemia. <b>2020</b> , 21, 34	2
770	Clinical potential of introducing next-generation sequencing in patients at relapse of acute myeloid leukemia. <b>2020</b> , 38, 425-431	4
769	How I treat acute myeloid leukemia in the era of new drugs. <b>2020</b> , 135, 85-96	104
768	Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia. <b>2020</b> , 135, 463-471	147
767	Impact of NPM1/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia. <b>2020</b> , 135, 371-380	53
766	An update on the molecular pathogenesis and potential therapeutic targeting of AML with t(8;21)(q22;q22.1);RUNX1-RUNX1T1. <b>2020</b> , 4, 229-238	23
765	Gilteritinib: potent targeting of FLT3 mutations in AML. <b>2020</b> , 4, 1178-1191	35
764	Combination of dasatinib with chemotherapy in previously untreated core binding factor acute myeloid leukemia: CALGB 10801. <b>2020</b> , 4, 696-705	21
763	Clinical implications of recurrent gene mutations in acute myeloid leukemia. <b>2020</b> , 9, 4	24
762	The Changing Landscape of Treatment in Acute Myeloid Leukemia. <b>2020</b> , 40, 1-12	5
761	Phenotype-based drug screening reveals association between venetoclax response and differentiation stage in acute myeloid leukemia. <b>2020</b> , 105, 708-720	40
760	Clinical practice recommendation on hematopoietic stem cell transplantation for acute myeloid leukemia patients with -internal tandem duplication: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <b>2020</b> , 105, 1507-1516	34
759	Isavuconazole as Primary Antifungal Prophylaxis in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome: An Open-label, Prospective, Phase 2 Study. <b>2021</b> , 72, 1755-1763	22
758	The Role of Somatic Mutations in Acute Myeloid Leukemia Pathogenesis. <b>2021</b> , 11,	2
757	How I diagnose and treat NPM1-mutated AML. <b>2021</b> , 137, 589-599	13
756	Prognostic impact of TP53 mutation, monosomal karyotype, and prior myeloid disorder in nonremission acute myeloid leukemia at allo-HSCT. <b>2021</b> , 56, 334-346	5
755	Management of patients with acute myeloid leukemia undergoing therapy with midostaurin: a focus on antifungal prophylaxis. <b>2021</b> , 39, 20-26	
754	Potential targeting of FLT3 acute myeloid leukemia. <b>2021</b> , 106, 671-681	11

753	Liaisons Dangereuses? new drugs, physicians and the drug industry. <b>2021</b> , 56, 299-302	1
752	Phase I Study of Alvocidib Followed by 7+3 (Cytarabine + Daunorubicin) in Newly Diagnosed Acute Myeloid Leukemia. <b>2021</b> , 27, 60-69	6
751	Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study. <b>2021</b> , 137, 1792-1803	51
750	LT-171-861, a novel FLT3 inhibitor, shows excellent preclinical efficacy for the treatment of FLT3 mutant acute myeloid leukemia. <b>2021</b> , 11, 93-106	6
749	A6 peptide-tagged, ultra-small and reduction-sensitive polymersomal vincristine sulfate as a smart and specific treatment for CD44+ acute myeloid leukemia. <b>2021</b> , 329, 706-716	3
748	Acute Leukemias. <b>2021</b> ,	2
747	Laboratory quality assessment of candidate gene panel testing for acute myeloid leukaemia: a joint ALLG / RCPAQAP initiative. <b>2021</b> , 53, 487-492	
746	New cancer therapies. Are haematopoietic cell transplants a dead duck?. <b>2021</b> , 56, 1086-1089	2
745	The genomic and biological complexity of mixed phenotype acute leukemia. <b>2021</b> , 58, 153-166	1
744	Natural small molecule triptonide inhibits lethal acute myeloid leukemia with FLT3-ITD mutation by targeting Hedgehog/FLT3 signaling. <b>2021</b> , 133, 111054	2
743	Patterns of Resistance Differ in Patients with Acute Myeloid Leukemia Treated with Type I versus Type II FLT3 inhibitors. <b>2021</b> , 2, 125-134	13
742	ELN risk stratification and outcomes in secondary and therapy-related AML patients consolidated with allogeneic stem cell transplantation. <b>2021</b> , 56, 936-945	5
741	Early assessment of clofarabine effectiveness based on measurable residual disease, including AML stem cells. <b>2021</b> , 137, 1694-1697	7
740	Synergy of FLT3 inhibitors and the small molecule inhibitor of LIM kinase1/2 CEL_Amide in FLT3-ITD mutated Acute Myeloblastic Leukemia (AML) cells. <b>2021</b> , 100, 106490	1
739	Midostaurin after allogeneic stem cell transplant in patients with FLT3-internal tandem duplication-positive acute myeloid leukemia. <b>2021</b> , 56, 1180-1189	22
738	Clinical characteristics and outcomes in patients with acute myeloid leukemia with concurrent FLT3-ITD and IDH mutations. <b>2021</b> , 127, 381-390	5
737	Invasive Mold Infections in FLT3-Mutated Acute Myeloid Leukemia. <b>2021</b> , 21, e477-e482	3
736	Therapy for acute myelogenous leukemia revisited: moving away from a one-size-fits-all approach. <b>2021</b> , 21, 5-8	1

735	Selective inhibition of aldo-keto reductase 1C3: a novel mechanism involved in midostaurin and daunorubicin synergism. <b>2021</b> , 95, 67-78	3
734	Midostaurin in combination with chemotherapy is most effective in patients with acute myeloid leukemia presenting with high FLT3-ITD allelic ratio who proceed to allogeneic stem cell transplantation while in first complete remission. <b>2021</b> , 106, 64-71	1
733	A personalized approach to guide allogeneic stem cell transplantation in younger adults with acute myeloid leukemia. <b>2021</b> , 137, 524-532	7
732	Hematopoietic Cell Transplantation in the Treatment of Newly Diagnosed Adult Acute Myeloid Leukemia: An Evidence-Based Review from the American Society of Transplantation and Cellular Therapy. <b>2021</b> , 27, 6-20	12
731	Management of fever and neutropenia in the adult patient with acute myeloid leukemia. <b>2021</b> , 19, 359-378	4
730	Recent advances of targeted therapy in relapsed/refractory acute myeloid leukemia. <b>2021</b> , 21, 409-421	1
729	Post-Transplant Maintenance Therapy for Patients with Acute Myeloid Leukemia: Current Approaches and the Need for More Trials. <b>2021</b> , 12, 21-32	1
728	Diagnosis and Classification of AML: WHO 2016. <b>2021</b> , 23-54	0
727	Serine Biosynthesis Is a Metabolic Vulnerability in FLT3-ITD-Driven Acute Myeloid Leukemia. <b>2021</b> , 11, 1582-1599	11
726	MRD Tailored Therapy in AML: What We Have Learned So Far. <b>2020</b> , 10, 603636	8
725	Real-life experience with CPX-351 and impact on the outcome of high-risk AML patients: a multicentric French cohort. <b>2021</b> , 5, 176-184	21
724	Application of gene mutation analysis in hematopoietic stem cell transplantation for acute myeloid leukemia. <b>2021</b> , 10, 16-22	
723	Bypass, Escape, or Mutate: The Resistant Clones in Midostaurin-treated FLT3-ITD AML. <b>2021</b> , 18,	
722	Treatment of Relapsed and Refractory AML: Intensive Approach in Fit Patients. <b>2021</b> , 233-240	
721	Current status of immunotherapy in acute myeloid leukemia. <b>2021</b> , 271, 03025	
720	and Gene Mutations in Acute Myeloid Leukemia. <b>2021</b> , 15, 15-26	
719	Pre-clinical development of a novel CD3-CD123 bispecific T-cell engager using cross-over dual-variable domain (CODV) format for acute myeloid leukemia (AML) treatment. <b>2021</b> , 10, 1945803	0
718	Maintenance therapy for -mutated acute myeloid leukemia. <b>2021</b> , 106, 664-670	5

717	Acute Myeloid Leukemia and Allogeneic Hematopoietic Cell Transplant. <b>2021</b> , 231-250	
716	Clinical Manifestation and Diagnostic Workup. <b>2021</b> , 119-126	
715	Dual Kinase Targeting in Leukemia. <b>2021</b> , 13,	1
714	A review of FDA-approved acute myeloid leukemia therapies beyond '7 + 3'. <b>2021</b> , 14, 185-197	13
713	Advances in therapeutic options for newly diagnosed, high-risk AML patients. <b>2021</b> , 12, 20406207211001138	3
712	Saikosaponin D exhibits anti-leukemic activity by targeting FTO/mA signaling. <b>2021</b> , 11, 5831-5846	13
711	Acute Myeloid Leukemia. <b>2021</b> , 110-141	
710	Future Developments: Novel Agents. <b>2021</b> , 293-315	0
709	Future Developments: Measurable Residual Disease. <b>2021</b> , 317-337	
708	Treatment of Newly Diagnosed AML in Fit Patients. <b>2021</b> , 199-213	
707	Acute Myeloid Leukemia in Children: Emerging Paradigms in Genetics and New Approaches to Therapy. <b>2021</b> , 23, 16	8
706	Bacon-Wrapped Chemo: Can Liposomal Cytarabine/Daunomycin Improve Outcomes for Children With Newly Diagnosed AML Versus Conventional Therapy?. <b>2021</b> , 18,	
705	APR-246 induces early cell death by ferroptosis in acute myeloid leukemia. <b>2021</b> ,	26
704	Molecular Targeted Therapy in Myelodysplastic Syndromes: New Options for Tailored Treatments. <b>2021</b> , 13,	6
703	Characteristics and outcome of patients with acute myeloid leukaemia and t(8;16)(p11;p13): results from an International Collaborative Study. <b>2021</b> , 192, 832-842	4
702	A Phase II Trial of Imatinib Mesylate as Maintenance Therapy for Patients With Newly Diagnosed C-kit-positive Acute Myeloid Leukemia. <b>2021</b> , 21, 113-118	2
701	Data from French named patient program of quizartinib in relapsed/refractory acute myeloid leukemia. <b>2021</b> , 62, 1756-1760	1
700	Künstliche Intelligenz und Next Generation Sequencing. <b>2021</b> , 12, 8-13	

699	Gene expression profiling identifies FLT3 mutation-like cases in wild-type FLT3 acute myeloid leukemia. <b>2021</b> , 16, e0247093	0
698	Antileukemic efficacy of a potent artemisinin combined with sorafenib and venetoclax. <b>2021</b> , 5, 711-724	4
697	High expression predicts poor survival in non-M3 acute myeloid leukemia. <b>2021</b> , 246, 1184-1197	0
696	Acute myeloid leukemia: current progress and future directions. <b>2021</b> , 11, 41	64
695	Emerging Immunotherapy for Acute Myeloid Leukemia. <b>2021</b> , 22,	8
694	Dysregulation of miR-138-5p/RPS6KA1-AP2M1 Is Associated With Poor Prognosis in AML. <b>2021</b> , 9, 641629	5
693	PP2A-activating Drugs Enhance FLT3 Inhibitor Efficacy through AKT Inhibition-Dependent GSK-3 $\beta$ Mediated c-Myc and Pim-1 Proteasomal Degradation. <b>2021</b> , 20, 676-690	1
692	Sorafenib or placebo in patients with newly diagnosed acute myeloid leukaemia: long-term follow-up of the randomized controlled SORAML trial. <b>2021</b> , 35, 2517-2525	10
691	Applications of next-generation sequencing in hematologic malignancies. <b>2021</b> , 82, 859-870	0
690	Incorporation of Novel therapies for the treatment of acute myeloid leukemia: a perspective. <b>2021</b> , 62, 779-790	0
689	Correction to: Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML. <b>2021</b> , 14, 34	1
688	Clinical impact of panel-based error-corrected next generation sequencing versus flow cytometry to detect measurable residual disease (MRD) in acute myeloid leukemia (AML). <b>2021</b> , 35, 1392-1404	10
687	Genomic characterization of relapsed acute myeloid leukemia reveals novel putative therapeutic targets. <b>2021</b> , 5, 900-912	4
686	Clinical Implications of Inflammation in Acute Myeloid Leukemia. <b>2021</b> , 11, 623952	6
685	Two decades of targeted therapies in acute myeloid leukemia. <b>2021</b> , 35, 651-660	13
684	The application of BH3 mimetics in myeloid leukemias. <b>2021</b> , 12, 222	9
683	Safety profile and impact on survival of tyrosine kinase inhibitors versus conventional therapy in relapse or refractory FLT3 positive acute myeloid leukemia patients. <b>2021</b> , 101, 106497	1
682	Matched Targeted Therapy for Pediatric Patients with Relapsed, Refractory, or High-Risk Leukemias: A Report from the LEAP Consortium. <b>2021</b> , 11, 1424-1439	4



681	Heterogeneous nuclear ribonucleoprotein K is overexpressed in acute myeloid leukemia and causes myeloproliferative disease in mice via altered Runx1 splicing.	0
680	Cytoplasmic DROSHA and non-canonical mechanisms of MiR-155 biogenesis in FLT3-ITD acute myeloid leukemia. <b>2021</b> , 35, 2285-2298	4
679	Advances and unanswered questions in management of acute myeloid leukemia in older adults: A glimpse into the future. <b>2021</b> , 12, 980-984	0
678	Multiplexed single-cell mass cytometry reveals distinct inhibitory effects on intracellular phosphoproteins by midostaurin in combination with chemotherapy in AML cells. <b>2021</b> , 10, 7	0
677	Maintenance Therapy in AML. <b>2020</b> , 10, 619085	1
676	CDK6 Is a Potential Prognostic Biomarker in Acute Myeloid Leukemia. <b>2020</b> , 11, 600227	2
675	Descriptive and Functional Genomics in Acute Myeloid Leukemia (AML): Paving the Road for a Cure. <b>2021</b> , 13,	5
674	FDA Approval Summary: Gilteritinib for Relapsed or Refractory Acute Myeloid Leukemia with a Mutation. <b>2021</b> , 27, 3515-3521	15
673	Choosing Antifungals for the Midostaurin-Treated Patient: Does CYP3A4 Outweigh Recommendations? A Brief Insight from Real Life. <b>2021</b> , 66, 47-52	3
672	Expression of a recombinant FLT3 ligand and its emtansine conjugate as a therapeutic candidate against acute myeloid leukemia cells with FLT3 expression. <b>2021</b> , 20, 67	1
671	What Is the Best Choice and Dose of Anthracycline for Induction Chemotherapy in Acute Myeloid Leukemia?.	
670	Target Therapy in Acute Myeloid Leukemia.	
669	Treatment of AML in Older Patients.	
668	Differentiation syndrome with lower-intensity treatments for acute myeloid leukemia. <b>2021</b> , 96, 735-746	2
667	FLT3 Inhibitors in Acute Myeloid Leukemia: Challenges and Recent Developments in Overcoming Resistance. <b>2021</b> , 64, 2878-2900	12
666	Acute myeloid leukemia: Treatment and research outlook for 2021 and the MD Anderson approach. <b>2021</b> , 127, 1186-1207	18
665	Realizing Innate Potential: CAR-NK Cell Therapies for Acute Myeloid Leukemia. <b>2021</b> , 13,	9
664	Is there evidence for the use of FLT3 inhibitors as maintenance therapy in AML?. <b>2021</b> , 34, 101246	

663	OTS167 blocks FLT3 translation and synergizes with FLT3 inhibitors in FLT3 mutant acute myeloid leukemia. <b>2021</b> , 11, 48	3
662	Targeting acute myeloid leukemia dependency on VCP-mediated DNA repair through a selective second-generation small-molecule inhibitor. <b>2021</b> , 13,	6
661	The evolving concept of indications for allogeneic hematopoietic cell transplantation during first complete remission of acute myeloid leukemia. <b>2021</b> , 56, 1257-1265	4
660	Momelotinib is a highly potent inhibitor of FLT3-mutant AML.	0
659	Precision Medicine Treatment in Acute Myeloid Leukemia Is Not a Dream. <b>2021</b> , 2, 131-153	2
658	Treatment options for older unfit patients with acute myeloid leukemia. <b>2021</b> , 17, 837-851	
657	miR-621 May Suppress Cell Proliferation via Targeting lncRNA SNHG10 in Acute Myeloid Leukemia. <b>2021</b> , 13, 2117-2123	3
656	FMS-like Tyrosine Kinase 3-Internal Tandem Duplication Allele Concentrations Should Be Determined in a Mutation-Type-Specific Manner. <b>2021</b> , 67, 691-693	
655	Estimands in hematologic oncology trials. <b>2021</b> , 20, 793-805	0
654	TKI Maintenance After Stem-Cell Transplantation for -ITD Positive Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis. <b>2021</b> , 12, 630429	2
653	Mayo Clinic experience with 1123 adults with acute myeloid leukemia. <b>2021</b> , 11, 46	1
652	Emerging agents and regimens for AML. <b>2021</b> , 14, 49	18
651	Improved Variant Detection in Clinical Myeloid NGS Testing by Supplementing a Commercial Myeloid NGS Assay with Custom or Extended Data Filtering and Accessory Fragment Analysis. <b>2021</b> , 25, 251-266	0
650	Experience with FLT3 Inhibitor Midostaurin in Newly Diagnosed Acute Myeloid Leukemia Patients.	
649	Novel Targeted Therapeutics in Acute Myeloid Leukemia: an Embarrassment of Riches. <b>2021</b> , 16, 192-206	1
648	Phase I study of ADI-PEG20 plus low-dose cytarabine for the treatment of acute myeloid leukemia. <b>2021</b> , 10, 2946-2955	5
647	Defining the Optimal Total Number of Chemotherapy Courses in Younger Patients With Acute Myeloid Leukemia: A Comparison of Three Versus Four Courses. <b>2021</b> , 39, 890-901	7
646	New Treatment Options for Older Patients with Acute Myeloid Leukemia. <b>2021</b> , 22, 39	2

645	Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603/RATIFY trial. <b>2021</b> , 35, 2539-2551	15
644	Which novel agents will have a clinically meaningful impact in AML at diagnosis?. <b>2021</b> , 34, 101257	2
643	Healthcare resource utilization in adult patients with relapsed/refractory FLT3 mutated acute myeloid leukemia: A retrospective chart review from Spain. <b>2021</b> , 106, 724-733	0
642	Drug ranking using machine learning systematically predicts the efficacy of anti-cancer drugs. <b>2021</b> , 12, 1850	21
641	Role of thermal fluctuations in biological copying mechanisms. <b>2021</b> , 103, 032110	1
640	Mechanisms of Resistance of New Target Drugs in Acute Myeloid Leukemia.	
639	The important role of intensive induction chemotherapy in the treatment of acute myeloid leukemia. <b>2021</b> , 14, 303-314	0
638	Combined inhibition of XIAP and BCL2 drives maximal therapeutic efficacy in genetically diverse aggressive acute myeloid leukemia.. <b>2021</b> , 2, 340-356	0
637	Prediction of clinical outcomes through assessment of sarcopenia and adipopenia using computed tomography in adult patients with acute myeloid leukemia. <b>2021</b> , 114, 44-52	5
636	FLT3-ITDs and FLT3-ITDon'ts: navigating maintenance therapy in FLT3-ITD-positive acute myeloid leukemia following stem cell transplantation. <b>2021</b> , 56, 1774-1776	0
635	Precision medicine in myeloid malignancies. <b>2021</b> ,	5
634	Optimizing Transplant Approaches and Post-Transplant Strategies for Patients With Acute Myeloid Leukemia. <b>2021</b> , 11, 666091	4
633	A phase I/II study of the combination of quizartinib with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. <b>2021</b> , 106, 2121-2130	10
632	Post-transplantation maintenance with sorafenib or midostaurin for FLT3 positive AML patients - a multicenter retrospective observational study. <b>2021</b> , 62, 2475-2481	2
631	Long-Term Outcomes After Autologous Versus Allogeneic Stem Cell Transplantation in Molecularly-Stratified Patients With Intermediate Cytogenetic Risk Acute Myeloid Leukemia: A PETHEMA Study. <b>2021</b> , 27, 311.e1-311.e10	0
630	Design, implementation and clinical utility of next generation sequencing in myeloid malignancies: acute myeloid leukaemia and myelodysplastic syndrome. <b>2021</b> , 53, 328-338	1
629	The influence of delay in mononuclear cell isolation on acute myeloid leukemia phosphorylation profiles. <b>2021</b> , 238, 104134	2
628	The safety profile of FLT3 inhibitors in the treatment of newly diagnosed or relapsed/refractory acute myeloid leukemia. <b>2021</b> , 20, 791-799	1

627	Personalized patient care with aggressive hematological malignancies in non-responders to first-line treatment. <b>2021</b> , 6, 203-215	0
626	Genetic alterations in Thai adult patients with acute myeloid leukemia and myelodysplastic syndrome-excess blasts detected by next-generation sequencing technique. <b>2021</b> , 100, 1983-1993	
625	Combining Mass Spectrometry-Based Phosphoproteomics with a Network-Based Approach to Reveal FLT3-Dependent Mechanisms of Chemoresistance. <b>2021</b> , 9,	0
624	The promised land. <b>2021</b> , 106, 2039	
623	SIRT5 IS A DRUGGABLE METABOLIC VULNERABILITY IN ACUTE MYELOID LEUKEMIA. <b>2021</b> , 2, 266-287	6
622	How I Treat Adult Acute Myeloid Leukemia. <b>2021</b> , 42, 182-189	0
621	An evolutionary approach to clonally complex hematologic disorders. <b>2021</b> , 2, 201-215	1
620	Impact of age, functional status, and comorbidities on quality of life and outcomes in elderly patients with AML: review. <b>2021</b> , 100, 1359-1376	1
619	Deletions in FLT-3 juxtamembrane domain define a new class of pathogenic mutations: case report and systematic analysis. <b>2021</b> , 5, 2285-2293	4
618	De novo acute myeloid leukemia: A population-based study of outcome in the United States based on the Surveillance, Epidemiology, and End Results (SEER) database, 1980 to 2017. <b>2021</b> , 127, 2049-2061	18
617	Treatment of acute myeloid leukemia in children: A practical perspective. <b>2021</b> , 68, e28979	4
616	Multi-Site 11-Year Experience of Less-Intensive versus Intensive Therapies in Acute Myeloid Leukemia. <b>2021</b> ,	6
615	References. <b>2021</b> , 503-522	
614	Inhibitory effects of Tomivosertib in acute myeloid leukemia. <b>2021</b> , 12, 955-966	1
613	Acute myeloid leukaemia in patients we judge as being older and/or unfit. <b>2021</b> , 290, 279-293	1
612	Updates in Childhood Leukemia. <b>2021</b> , 1, 169-180	
611	The impact of centralised care of younger AML patients on treatment results: a retrospective analysis of real-world data from a national population-based registry. <b>2021</b> , 60, 818-823	
610	The Role of Metabolism in the Development of Personalized Therapies in Acute Myeloid Leukemia. <b>2021</b> , 11, 665291	1

609	Targeted Therapeutic Approach Based on Understanding of Aberrant Molecular Pathways Leading to Leukemic Proliferation in Patients with Acute Myeloid Leukemia. <b>2021</b> , 22,	3
608	FLT3-ITD mutations in acute myeloid leukaemia - molecular characteristics, distribution and numerical variation. <b>2021</b> , 15, 2300-2317	0
607	DNMT3A harboring leukemia-associated mutations directs sensitivity to DNA damage at replication forks.	
606	FLT3 inhibitor based induction and allogeneic stem cell transplant in complete remission 1 improve outcomes in patients with newly diagnosed Acute Myeloid Leukemia with very low FLT3 allelic burden. <b>2021</b> , 96, E275-E279	2
605	Künstliche Intelligenz und Next Generation Sequencing. <b>2021</b> , 42, 373-377	
604	Role of CXCR4 in the progression and therapy of acute leukaemia. <b>2021</b> , 54, e13076	6
603	SF3B1 as therapeutic target in FLT3/ITD positive acute myeloid leukemia. <b>2021</b> , 35, 2698-2702	1
602	Quantification of eight hematological tyrosine kinase inhibitors in both plasma and whole blood by a validated LC-MS/MS method. <b>2021</b> , 226, 122140	6
601	Towards precision medicine for AML. <b>2021</b> , 18, 577-590	21
600	Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia: Who, When, and How?. <b>2021</b> , 12, 659595	6
599	Advances in Management for Older Adults With Hematologic Malignancies. <b>2021</b> , 39, 2102-2114	3
598	FLT3 Tyrosine Kinase Inhibitors for the Treatment of Fit and Unfit Patients with FLT3-Mutated AML: A Systematic Review. <b>2021</b> , 22,	2
597	BiTEs, DARTS, BiKEs and TriKEs-Are Antibody Based Therapies Changing the Future Treatment of AML?. <b>2021</b> , 11,	6
596	Genetic identification of patients with AML older than 60 years achieving long-term survival with intensive chemotherapy. <b>2021</b> , 138, 507-519	7
595	Childhood Cancer: Occurrence, Treatment and Risk of Second Primary Malignancies. <b>2021</b> , 13,	5
594	FLT3 mutated acute myeloid leukemia: 2021 treatment algorithm. <b>2021</b> , 11, 104	14
593	Focus on Novel Therapies for Older Adults with Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndromes. <b>2021</b> , 1, 237-248	0
592	Small molecules in targeted cancer therapy: advances, challenges, and future perspectives. <b>2021</b> , 6, 201	103

591	Sex disparity in acute myeloid leukaemia with FLT3 internal tandem duplication mutations: implications for prognosis. <b>2021</b> , 15, 2285-2299	0
590	Interrogation of novel CDK2/9 inhibitor fadraciclib (CYC065) as a potential therapeutic approach for AML. <b>2021</b> , 7, 137	3
589	Eradication of Measurable Residual Disease in AML: A Challenging Clinical Goal. <b>2021</b> , 13,	1
588	Clinical Benefits and Safety of FMS-Like Tyrosine Kinase 3 Inhibitors in Various Treatment Stages of Acute Myeloid Leukemia: A Systematic Review, Meta-Analysis, and Network Meta-Analysis. <b>2021</b> , 11, 686013	0
587	Efficacy and Safety Profile of Ivosidenib in the Management of Patients with Acute Myeloid Leukemia (AML): An Update on the Emerging Evidence. <b>2021</b> , 11, 41-54	3
586	Treatment for Relapsed/Refractory Acute Myeloid Leukemia. <b>2021</b> , 5, e572	4
585	Real world use of FLT3 inhibitors for treatment of FLT3+ acute myeloid leukemia (AML): A single center, propensity-score matched, retrospective cohort study. <b>2021</b> , 10781552211020815	0
584	Inhibition of translation initiation factor eIF4a inactivates heat shock factor 1 (HSF1) and exerts anti-leukemia activity in AML. <b>2021</b> , 35, 2469-2481	3
583	Distinguishing AML from MDS: a fixed blast percentage may no longer be optimal. <b>2021</b> ,	14
582	Risk adapted therapeutic strategy in newly diagnosed acute myeloid leukemia: Refining the outcomes of ELN 2017 intermediate-risk patients. <b>2021</b> , 105, 106568	2
581	The contribution of single-cell analysis of acute leukemia in the therapeutic strategy. <b>2021</b> , 9, 50	2
580	Therapeutic implications of menin inhibition in acute leukemias. <b>2021</b> , 35, 2482-2495	14
579	Transcript-Level Dysregulation of Family Genes in Acute Myeloblastic Leukemia. <b>2021</b> , 13,	3
578	Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin. <b>2021</b> , 137, 3093-3104	19
577	A precision medicine classification for treatment of acute myeloid leukemia in older patients. <b>2021</b> , 14, 96	1
576	Myelodysplastic Syndromes in the Postgenomic Era and Future Perspectives for Precision Medicine. <b>2021</b> , 13,	0
575	Open-Label Phase II Prospective, Randomized, Controlled Study of Romyelocel-L Myeloid Progenitor Cells to Reduce Infection During Induction Chemotherapy for Acute Myeloid Leukemia. <b>2021</b> , 39, 3261-3272	1
574	Mitochondrial metabolism: powering new directions in acute myeloid leukemia. <b>2021</b> , 62, 2331-2341	1

573	Fms-like tyrosine kinase 3-internal tandem duplications epigenetically activates checkpoint kinase 1 in acute myeloid leukemia cells. <b>2021</b> , 11, 13236	0
572	Targeted and cytotoxic therapies as maintenance treatment for non-transplant eligible patients with acute myeloid leukemia. <b>2021</b> , 50, 100863	1
571	Investigation of the Osteopontin isoforms expression in patients with acute myeloid leukemia. <b>2021</b> , 38, 102	
570	A method for overcoming plasma protein inhibition of tyrosine kinase inhibitors. <b>2021</b> , 2, 532-547	0
569	Analysis of FLT3-Activating Mutations in Patients With Acute Myelogenous Leukemia in Jordan: Association With FAB Subtypes and Identification of Subgroups With Poor Prognosis. <b>2021</b> , 21, e588-e597	1
568	A guideline for the outpatient management of glycaemic control in people with cancer. <b>2021</b> , e14636	2
567	Management Approach to Acute Myeloid Leukemia Leveraging the Available Resources in View of the Latest Evidence: Consensus of the Saudi Society of Blood and Marrow Transplantation. <b>2021</b> , 7, 1220-1232	1
566	The Protein Kinase Inhibitor Midostaurin Improves Functional Neurological Recovery and Attenuates Inflammatory Changes Following Traumatic Cervical Spinal Cord Injury. <b>2021</b> , 11,	1
565	Biallelic TET2 mutation sensitizes to 5-azacytidine in acute myeloid leukemia.	
564	Impact of induction chemotherapy with intermediate-dosed cytarabine and subsequent allogeneic stem cell transplantation on the outcome of high-risk acute myeloid leukemia. <b>2021</b> , 1	0
563	The beginning of a new therapeutic era in acute myeloid leukemia. <b>2021</b> , 2, 823	0
562	Maintenance therapy after allogeneic hematopoietic transplant for acute myeloid leukemia: a systematic review and meta-analysis. <b>2021</b> , 60, 1335-1341	3
561	Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study results. <b>2021</b> ,	4
560	Post-Induction Treatment for Acute Myeloid Leukemia: Something Change?. <b>2021</b> , 23, 109	0
559	Dose intensity for induction in acute myeloid leukemia: what, when, and for whom?. <b>2021</b> , 106, 2544-2554	1
558	A 2:1 randomized, open-label, phase II study of selinexor vs. physician's choice in older patients with relapsed or refractory acute myeloid leukemia. <b>2021</b> , 62, 3192-3203	1
557	The development of 3-substituted indolin-2-one derivatives as kinase inhibitors for cancer therapy. <b>2021</b> ,	1
556	Treatment-induced arteriolar revascularization and miR-126 enhancement in bone marrow niche protect leukemic stem cells in AML. <b>2021</b> , 14, 122	3

555	Pim kinase inhibitor co-treatment decreases alternative non-homologous end-joining DNA repair and genomic instability induced by topoisomerase 2 inhibitors in cells with FLT3 internal tandem duplication. <b>2021</b> , 12, 1763-1779	0
554	Post-transplant maintenance therapy for MDS and AML: a bridge too far or the beginning of a new era?. <b>2021</b> , 62, 3073-3077	
553	Novel CAR T therapy is a ray of hope in the treatment of seriously ill AML patients. <b>2021</b> , 12, 465	12
552	The EHA Research Roadmap: Malignant Myeloid Diseases. <b>2021</b> , 5, e635	0
551	Targeting leukemia-specific dependence on the de novo purine synthesis pathway. <b>2021</b> ,	3
550	Characteristics and outcome of patients with core binding factor acute myeloid leukemia and -ITD: results from an international collaborative study. <b>2021</b> ,	1
549	Updates on targeted therapies for acute myeloid leukaemia. <b>2021</b> ,	10
548	Midostaurin-induced Sweet syndrome in a patient with FLT3-ITD-positive AML. <b>2021</b> , 14,	3
547	3+7 Combined Chemotherapy for Acute Myeloid Leukemia: Is It Time to Say Goodbye?. <b>2021</b> , 23, 120	2
546	Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial. <b>2021</b> , 8, e552-e561	19
545	Real-World Outcomes of Patients with Acute Myeloid Leukemia in Taiwan: A Nationwide Population-Based Study, 2011-2015. <b>2021</b> , 21, e649-e657	
544	Trials and Tribulations in the Frontline Treatment of Older Adults with Acute Myeloid Leukemia. <b>2021</b> , 2, 515-544	
543	Clinical Utility of Fedratinib in Myelofibrosis. <b>2021</b> , 14, 4509-4521	1
542	When it comes to drug access, should children be considered small adults? Countering coverage denials of FLT3 inhibitors in children with FLT3-ITD AML. <b>2021</b> , 68, e29278	0
541	Targeted Therapy in Pediatric AML: An Evolving Landscape. <b>2021</b> , 23, 485-497	0
540	The long shadow of socioeconomic deprivation over the modern management of acute myeloid leukemia: time to unravel the challenges. <b>2021</b> , 11, 141	0
539	Double Drop-Off Droplet Digital PCR: A Novel, Versatile Tool for Mutation Screening and Residual Disease Monitoring in Acute Myeloid Leukemia Using Cellular or Cell-Free DNA. <b>2021</b> , 23, 975-985	0
538	Maintenance therapies in acute myeloid leukemia: the renaissance of an old therapeutic concept. <b>2021</b> , 33, 658-669	1



537	Safety of FLT3 inhibitors in patients with acute myeloid leukemia. <b>2021</b> , 14, 851-865	2
536	FLT3-ITD signals bad news for core binding factor acute myeloid leukemia unless trisomy 22 comes to the rescue. <b>2021</b> ,	
535	Case 26-2021: A 49-Year-Old Man with Relapsed Acute Myeloid Leukemia. <i>New England Journal of Medicine</i> , <b>2021</b> , 385, 834-843	59.2
534	Is venetoclax the new backbone of acute myeloid leukaemia therapy?. <b>2021</b> , 8, e536-e537	1
533	Validation, Implementation, and Clinical Impact of the OncoPrint Myeloid Targeted-Amplicon DNA and RNA Ion Semiconductor Sequencing Assay. <b>2021</b> , 23, 1292-1305	0
532	Metabolic Profiling during Acute Myeloid Leukemia Progression Using Paired Clinical Bone Marrow Serum Samples. <b>2021</b> , 11,	1
531	Inhibition of FLT3: A Prototype for Molecular Targeted Therapy in Acute Myeloid Leukemia. <b>2021</b> , 7, 1354-1354	
530	Gilteritinib versus chemotherapy in Japanese patients with FLT3-mutated relapsed/refractory acute myeloid leukemia. <b>2021</b> , 26, 2131-2141	1
529	Acute myeloid leukemia: Therapy resistance and a potential role for tetraspanin membrane scaffolds. <b>2021</b> , 137, 106029	1
528	Can the New and Old Drugs Exert an Immunomodulatory Effect in Acute Myeloid Leukemia?. <b>2021</b> , 13,	1
527	Acquisition of IDH2 mutations in relapsed/refractory AML is associated with worse patient outcomes. <b>2021</b> , 107, 609-616	
526	Dual Inhibition of FLT3 and AXL by Gilteritinib Overcomes Hematopoietic Niche-Driven Resistance Mechanisms in -ITD Acute Myeloid Leukemia. <b>2021</b> , 27, 6012-6025	2
525	Consolidation in AML: Abundant opinion and much unknown. <b>2021</b> , 51, 100873	0
524	FMS-Like Tyrosine Kinase 3 Inhibitors for the Treatment of Acute Myeloid Leukemia. <b>2021</b> ,	1
523	Case Report: A Novel Activating FLT3 Mutation in Acute Myeloid Leukemia. <b>2021</b> , 11, 728613	2
522	Biomarkers in Acute Myeloid Leukemia: Leveraging Next Generation Sequencing Data for Optimal Therapeutic Strategies. <b>2021</b> , 11, 748250	0
521	The differential effect of disease status at allogeneic hematopoietic cell transplantation on outcomes in acute myeloid and lymphoblastic leukemia. <b>2021</b> , 100, 3017-3027	
520	Harnessing the Therapeutic Value of Venetoclax: A Breakthrough Therapy in Acute Myeloid Leukemia. <b>2021</b> , 39, 2742-2748	0

519	Survivin' Acute Myeloid Leukaemia-A Personalised Target for inv(16) Patients. <b>2021</b> , 22,	2
518	Polymeric nanomedicines targeting hematological malignancies. <b>2021</b> , 337, 571-588	4
517	Mitochondrial metabolism as a potential therapeutic target in myeloid leukaemia. <b>2021</b> ,	7
516	Detecting and preventing post-hematopoietic cell transplant relapse in AML. <b>2021</b> , 28, 380-388	
515	Predicting cancer drug TARGETS - TreAtment Response Generalized Elastic-neT Signatures. <b>2021</b> , 6, 76	2
514	Acute Myeloid Leukemia: Historical Perspective and Progress in Research and Therapy Over 5 Decades. <b>2021</b> , 21, 580-597	7
513	Clonal Architecture and Evolutionary Dynamics in Acute Myeloid Leukemias. <b>2021</b> , 13,	1
512	DJ4 Targets the Rho-Associated Protein Kinase Pathway and Attenuates Disease Progression in Preclinical Murine Models of Acute Myeloid Leukemia. <b>2021</b> , 13,	0
511	Hypomethylating Agents and FLT3 Inhibitors As Maintenance Treatment for Acute Myeloid Leukemia and Myelodysplastic Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation-A Systematic Review and Meta-Analysis. <b>2021</b> ,	2
510	Gilteritinib combination therapies in pediatric patients with FLT3-mutated acute myeloid leukemia. <b>2021</b> , 5, 5215-5219	1
509	Advances in the First Line Treatment of Pediatric Acute Myeloid Leukemia in the Polish Pediatric Leukemia and Lymphoma Study Group from 1983 to 2019. <b>2021</b> , 13,	1
508	Strategies targeting FLT3 beyond the kinase inhibitors. <b>2021</b> , 225, 107844	1
507	Significance of NPM1 Gene Mutations in AML. <b>2021</b> , 22,	5
506	Targeted Therapies for the Evolving Molecular Landscape of Acute Myeloid Leukemia. <b>2021</b> , 13,	2
505	Molecular Pathogenesis of Chronic Myelomonocytic Leukemia and Potential Molecular Targets for Treatment Approaches. <b>2021</b> , 11, 751668	0
504	AML and the art of remission maintenance. <b>2021</b> , 49, 100829	2
503	DNA vs cDNA FLT3-ITD allelic ratio and length measurements in adult acute myeloid leukemia. <b>2021</b> , 5, 4476-4479	1
502	Maintenance therapy after allogeneic transplant for acute myeloid leukemia: great expectations. <b>2021</b> , 62, 2306-2309	

501	Acute Myeloid Leukemia Patients Requiring Two Cycles of Intensive Induction for Attainment of Remission Experience Inferior Survival Compared with Patients Requiring a Single Course of Induction Chemotherapy. <b>2021,</b>	0
500	A clinically applicable gene expression-based score predicts resistance to induction treatment in acute myeloid leukemia. <b>2021, 5, 4752-4761</b>	
499	Outcomes of Adult Acute Myeloid Leukemia Treated With Gemtuzumab-Ozogamicin: Cue To Optimized Chemotherapy Backbone. <b>2021, 21, 613-620</b>	0
498	PARP1 as a therapeutic target in acute myeloid leukemia and myelodysplastic syndrome. <b>2021, 5, 4794-4805</b>	0
497	Effective Immunosurveillance After Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia. <b>2021, 13, 7411-7427</b>	0
496	Haematological malignancies in sub-Saharan Africa: east Africa as an example for improving care. <b>2021, 8, e756-e769</b>	2
495	Discovery and structure-activity relationship exploration of pyrazolo[1,5-a]pyrimidine derivatives as potent FLT3-ITD inhibitors. <b>2021, 48, 116422</b>	
494	AMELIORATE: early intensification in -mutated acute myeloid leukemia based on peripheral blast clearance - MYNERVA-GIMEMA AML1919 trial. <b>2021, 17, 3787-3796</b>	
493	Histone methyltransferase EZH2 epigenetically affects CCNA1 expression in acute myeloid leukemia. <b>2021, 87, 110144</b>	1
492	Importance of targeted therapies in acute myeloid leukemia. <b>2021, 107-133</b>	0
491	Genomic Landscape and Clonal Evolution of AML. <b>2021, 103-118</b>	
490	Selective ERBB2 and BCL2 Inhibition Is Synergistic for Mitochondrial-Mediated Apoptosis in MDS and AML Cells. <b>2021, 19, 886-899</b>	0
489	Secondary AML. <b>2021, 71-101</b>	
488	Impact of a 40-Gene Targeted Panel Test on Physician Decision Making for Patients With Acute Myeloid Leukemia. <b>2021, 5,</b>	2
487	The synthesis of biologically active indolocarbazole natural products. <b>2021, 38, 1794-1820</b>	6
486	Acute Myeloid Leukemia in Adults. <b>2019, 507-521</b>	3
485	Acute Myeloid Leukemia in Older Adults. <b>2020, 501-520</b>	1
484	Use of Minimal Residual Disease in Acute Myeloid Leukemia Therapy. <b>2020, 21, 8</b>	4

483	Current Approaches to Transplantation for FLT3-ITD AML. <b>2020</b> , 15, 1-8	3
482	New Treatment Options for Acute Myeloid Leukemia in 2019. <b>2019</b> , 21, 16	25
481	Current concepts and future directions for hemato-oncologic diagnostics. <b>2020</b> , 151, 102977	6
480	Anti-FLT3 nanoparticles for acute myeloid leukemia: Preclinical pharmacology and pharmacokinetics. <b>2020</b> , 324, 317-329	6
479	Knockdown of LncRNA CRNDE suppresses proliferation and P-glycoprotein-mediated multidrug resistance in acute myelocytic leukemia through the Wnt/ $\beta$ -catenin pathway. <b>2020</b> , 40,	5
478	Novel therapies for AML: a round-up for clinicians. <b>2020</b> , 13, 1389-1400	4
477	Maintenance therapy for acute myeloid leukemia: sustaining the pursuit for sustained remission. <b>2021</b> , 28, 110-121	1
476	Reprogramming of serine metabolism is an actionable vulnerability in FLT3-ITD driven acute myeloid leukaemia.	1
475	Sex disparity in acute myeloid leukemia – evidence from a study of FLT3-ITD mutated patients.	1
474	RNAi screening of the tyrosine kinome in primary patient samples of acute myeloid leukemia.	1
473	Personal tumor antigens in blood malignancies: genomics-directed identification and targeting. <b>2020</b> , 130, 1595-1607	7
472	A $\beta$ -tubulin-based megakaryocyte maturation reporter system identifies novel drugs that promote platelet production. <b>2018</b> , 2, 2262-2272	17
471	Does patient fitness play a role in determining first-line treatment of acute myeloid leukemia?. <b>2020</b> , 2020, 41-50	3
470	Decitabine combined with CAG regimen in the treatment of elderly patients with acute myeloid leukemia. <b>2020</b> , 36, 141-145	2
469	Midostaurin-Related Interstitial Lung Injury in FLT3 Acute Myeloid Leukemia Post-Allogeneic Transplant. <b>2019</b> , 10, 237-239	3
468	Inhibition of SDF-1-induced migration of oncogene-driven myeloid leukemia by the L-RNA aptamer (Spiegelmer), NOX-A12, and potentiation of tyrosine kinase inhibition. <b>2017</b> , 8, 109973-109984	9
467	FLT3-ITD induces expression of Pim kinases through STAT5 to confer resistance to the PI3K/Akt pathway inhibitors on leukemic cells by enhancing the mTORC1/Mcl-1 pathway. <b>2018</b> , 9, 8870-8886	18
466	Flow cytometric characterization of acute leukemia reveals a distinctive "blast gate" of murine T-lymphoblastic leukemia/lymphoma. <b>2018</b> , 9, 2320-2328	2

465	STK3 is a therapeutic target for a subset of acute myeloid leukemias. <b>2018</b> , 9, 25458-25473	5
464	Clonal heterogeneity of -ITD detected by high-throughput amplicon sequencing correlates with adverse prognosis in acute myeloid leukemia. <b>2018</b> , 9, 30128-30145	22
463	Effect of Fms-like tyrosine kinase 3 (FLT3) ligand (FL) on antitumor activity of gilteritinib, a FLT3 inhibitor, in mice xenografted with FL-overexpressing cells. <b>2019</b> , 10, 6111-6123	17
462	Genomic markers of midostaurin drug sensitivity in FLT3 mutated and FLT3 wild-type acute myeloid leukemia patients. <b>2020</b> , 11, 2807-2818	2
461	Resistance to venetoclax and hypomethylating agents in acute myeloid leukemia. <b>2021</b> , 4, 125-142	10
460	Targeting Immune Signaling Pathways in Clonal Hematopoiesis. <b>2019</b> , 26, 5262-5277	5
459	The Evolving AML Genomic Landscape: Therapeutic Implications. <b>2020</b> , 20, 532-544	3
458	FLT3 Inhibition in Acute Myeloid Leukaemia - Current Knowledge and Future Prospects. <b>2020</b> , 20, 513-531	4
457	FLT3 inhibitors in the treatment of acute myeloid leukemia: current status and future perspectives. <b>2020</b> , 111, 427-442	7
456	Current strategies for detection and approach to measurable residual disease in acute myeloid leukemia. <b>2020</b> , 111, 386-394	3
455	[Sorafenib - induced thyroiditis in patient with a relapse of acute myelomonocytic leukemia with FLT3-ITD mutation]. <b>2019</b> , 91, 93-97	0
454	Targeted variant detection using unaligned RNA-Seq reads. <b>2019</b> , 2,	5
453	Allogeneic Stem Cell Transplantation for FLT3-Mutated Acute Myeloid Leukemia: T-Cell Depletion and Posttransplant Sorafenib Maintenance Improve Survival. A Retrospective Acute Leukemia Working Party-European Society for Blood and Marrow Transplant Study. <b>2019</b> , 1, 58-74	26
452	Management of AML Beyond "3 + 7" in 2019. <b>2019</b> , 1, 10-18	5
451	Salvage Therapy after Allogeneic Hematopoietic Cell Transplantation: Targeted and Low-Intensity Treatment Options in Myelodysplastic Syndrome and Acute Myeloid Leukemia. <b>2019</b> , 1, 94-100	4
450	Genome-wide CRISPR screen identifies regulators of MAPK and MTOR pathways mediating sorafenib resistance in acute myeloid leukemia. <b>2020</b> , Online ahead of print,	5
449	Emerging epigenetic therapeutics for myeloid leukemia: modulating demethylase activity with ascorbate. <b>2021</b> , 106, 14-25	8
448	Differentiation therapy of myeloid leukemia: four decades of development. <b>2021</b> , 106, 26-38	8

447	Expanding dasatinib beyond KIT in acute myeloid leukemia. <b>2020</b> , 105, 2708-2710	1
446	CD38 knockout natural killer cells expressing an affinity optimized CD38 chimeric antigen receptor successfully target acute myeloid leukemia with reduced effector cell fratricide. <b>2020</b> , Online ahead of print,	25
445	Fludarabine, High-Dose Cytarabine and Idarubicin-Based Induction May Overcome the Negative Prognostic Impact of -ITD in Mutated AML, Irrespectively of -ITD Allelic Burden. <b>2020</b> , 13,	3
444	Location First: Targeting Acute Myeloid Leukemia Within Its Niche. <b>2020</b> , 9,	11
443	The Progress of Next Generation Sequencing in the Assessment of Myeloid Malignancies. <b>2019</b> , 36, 78-87	2
442	Treatments for children and adolescents with AML. <b>2020</b> , 55, S5-S13	4
441	New agents in acute myeloid leukemia (AML). <b>2020</b> , 55, S14-S18	4
440	Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology. <b>2019</b> , 17, 721-749	191
439	Current and Emerging Therapies for Acute Myeloid Leukemia. <b>2021</b> , 181, 57-73	0
438	Impact of next generation sequencing results on clinical management in patients with hematological disorders. <b>2021</b> , 62, 1702-1710	1
437	Activators and Inhibitors of Protein Kinase C (PKC): Their Applications in Clinical Trials. <b>2021</b> , 13,	3
436	Redefining the biological basis of lineage-ambiguous leukemia through genomics: BCL11B deregulation in acute leukemias of ambiguous lineage. <b>2021</b> , 34, 101329	1
435	Transcriptomic analysis reveals pro-inflammatory signatures associated with acute myeloid leukemia progression. <b>2021</b> ,	1
434	Risk factors affect accurate prognosis in ASXL1-mutated acute myeloid leukemia. <b>2021</b> , 21, 526	1
433	Is there an optimal adjunct therapy to traditional cytotoxic induction?. <b>2021</b> , 34, 101326	0
432	Immune Therapies for Myelodysplastic Syndromes and Acute Myeloid Leukemia. <b>2021</b> , 13,	2
431	MIDOSTAURIN ADDED TO CYTOSINE ARABINOSIDE PLUS IDARUBICIN (â+3â) IN NEWLY DIAGNOSED FLT3-MUTATED ACUTE MYELOID LEUKEMIA. <b>2021</b> , 43, S166-S167	
430	All patients with AML over 60 years of age should not be offered early allogeneic stem cell transplantation. <b>2021</b> ,	1

429	Molecular determinants of therapy response of venetoclax-based combinations in acute myeloid leukemia. <b>2021</b> , 402, 1547-1564	1
428	The cure of leukemia through the optimist's prism. <b>2021</b> , 128, 240	2
427	Advances in acute myeloid leukemia. <b>2021</b> , 375, n2026	16
426	Evolving Therapeutic Approaches for Older Patients with Acute Myeloid Leukemia in 2021. <b>2021</b> , 13,	5
425	New Drugs Bringing New Challenges to AML: A Brief Review. <b>2021</b> , 11,	0
424	Posttransplant blockade of CXCR4 improves leukemia complete remission rates and donor stem cell engraftment without aggravating GVHD. <b>2021</b> , 18, 2541-2553	0
423	Harnessing the benefits of available targeted therapies in acute myeloid leukaemia. <b>2021</b> , 8, e922-e933	7
422	Better the cure you know: why patients with AML ≥80 years of age should be offered early allogeneic stem cell transplantation. <b>2021</b> ,	0
421	Is allogeneic transplantation the preferred therapy for older patients with acute myeloid leukemia?. <b>2021</b> ,	
420	A comprehensive approach to therapy of haematological malignancies in older patients. <b>2021</b> , 8, e840-e852	2
419	Acute Leukemias. <b>2017</b> ,	
418	UCB HCT in FLT3+ AML. <b>2017</b> , 8, 81733-81734	
417	Neue Arzneimittel 2017. <b>2018</b> , 53-148	
416	Target variant detection in leukemia using unaligned RNA-Seq reads.	2
415	Classes of ITD predict outcomes in patients with AML treated with FLT3 inhibitors.	
414	Hypomethylating Agents for Treatment of Elderly Patients with Refractory Acute Myeloid Leukemia - A Case Report with a Focused Review of Literature. <b>2018</b> , 10, e2734	
413	IV. Molecularly Target Therapy for Acute Myeloid Leukemia. <b>2018</b> , 107, 1294-1300	
412	Leveraging single cell RNA sequencing experiments to model intra-tumor heterogeneity.	

- 411 Subtractive Interaction Proteomics Reveal a Network of Signaling Pathways Activated by an Oncogenic Transcription Factor in Acute Myeloid Leukemia.
- 410 Immune Thrombocytopenia: Are We Stuck in the Mud or Is There Light at the End of the Tunnel?. **2019**, 1, 173-179
- 409 Acute Myeloid Leukemia in Older Adults. **2019**, 1-20
- 408 Midostaurin for FLT3-mutated Acute Myeloid Leukaemia – Considerations for Optimal Use. **2019**, 15, 43
- 407 Midostaurin for acute myeloid leukaemia, mastocytosis, and mast cell leukaemia. **2019**, 42, 73-74
- 406 STAT5-dependent regulation of CDC25A by miR-16 controls proliferation and differentiation in FLT3-ITD acute myeloid leukemia.
- 405 Loss of FBXO9 enhances proteasome activity and promotes aggressiveness in acute myeloid leukemia.
- 404 Drivers of topoisomerase II poisoning mimic and complement cytotoxicity in AML cells. **2019**, 10, 5298-5312 1
- 403 Prognosis and outcome of patients with acute myeloid leukemia based on mutation with or without additional abnormal cytogenetics. **2019**, 18, 6766-6774 6
- 402 Management of Hematologic Disease in Mastocytosis. **2020**, 231-255
- 401 A summary of the molecular testing recommended in acute myeloid leukemia. **2020**, 4, 012-017 0
- 400 BETing on rational combination therapy in mutant acute myeloid leukemia. **2021**, 106, 931-932
- 399 Developing Pathology Measures for the Quality Payment Program-Part I: A Quest for Meaningful Measures. **2020**, 144, 686-696 1
- 398 Novel and Emerging Treatment Strategies for Acute Myeloid Leukemia. **2020**, 18, 999-1003
- 397 Clinical Impact of Panel Based Error Corrected Next Generation Sequencing versus Flow Cytometry to Detect Measurable Residual Disease (MRD) in Acute Myeloid Leukemia (AML).
- 396 Targeted drugs in the treatment of acute myeloid leukemia in children. **2020**, 7, 78-85 1
- 395 DNMT3A Harboring Leukemia-Associated Mutations Directs Sensitivity to DNA Damage at Replication Forks. **2021**, 1
- 394 Biological Therapies in the Treatment of Cancer-Update and New Directions. **2021**, 22, 2



393	Prediction of early (4-week) mortality in acute myeloid leukemia with intensive chemotherapy. <b>2021,</b>	1
392	Optimizing management of acute leukemia in community centers and when to refer. <b>2020, 2020, 123-128</b>	1
391	FLT3 inhibition by olverembatinib (HQP1351) downregulates MCL-1 and synergizes with BCL-2 inhibitor lisaftoclax (APG-2575) in preclinical models of FLT3-ITD mutant acute myeloid leukemia. <b>2021, 15, 101244</b>	2
390	Sequential Targeted Treatment for a Geriatric Patient with Acute Myeloid Leukemia with Concurrent FLT3-TKD and IDH1 Mutations. <b>2021, 38, 40-43</b>	
389	Characterization and Mitigation of Fragmentation Enzyme-Induced Dual Stranded Artifacts.	
388	ERKRANKUNGEN DES BLUTES UND DES GERINNUNGSSYSTEMS, SOLIDE TUMOREN UND PRINZIPIEN DER INTERNISTISCHEN ONKOLOGIE. <b>2020, B-1-B30-3</b>	
387	Akute Leukämien. <b>2020, 375-402</b>	
386	FLT3-positive acute myeloid leukemia: an example of personalized approach. <b>2020, 4, 16</b>	
385	Outcomes of allogeneic stem cell transplantation for patients with t(6:9) AML- A strong case for allogeneic stem cell transplantation in first complete remission. <b>2020, 189, 806-808</b>	
384	Gilteritinib: A Novel FLT3 Inhibitor for Relapsed/Refractory Acute Myeloid Leukemia. <b>2020, 11, 104-108</b>	1
383	Modulation of FLT3-ITD Localization and Targeting of Distinct Downstream Signaling Pathways as Potential Strategies to Overcome FLT3-Inhibitor Resistance. <b>2021, 10,</b>	0
382	A unique role of p53 haploinsufficiency or loss in the development of acute myeloid leukemia with FLT3-ITD mutation. <b>2021,</b>	0
381	Mass Cytometry in Hematologic Malignancies: Research Highlights and Potential Clinical Applications. <b>2021, 11, 704464</b>	1
380	The IL-3, IL-5, and GM-CSF common receptor beta chain mediates oncogenic activity of FLT3-ITD-positive AML. <b>2021,</b>	1
379	Demethylating therapy increases anti-CD123 CAR T cell cytotoxicity against acute myeloid leukemia. <b>2021, 12, 6436</b>	4
378	ELN2017 risk stratification improves outcome prediction when applied to the prospective GIMEMA AML1310 protocol. <b>2021,</b>	0
377	A review of FLT3 inhibitors in acute myeloid leukemia. <b>2021, 52, 100905</b>	3
376	Therapy of Newly Diagnosed Acute Myeloid Leukemia (AML). <b>2021, 77-87</b>	

375	Novel and Investigational Therapies in Acute Myeloid Leukemia. <b>2021</b> , 133-144	
374	Künstliche Intelligenz und Next Generation Sequencing. <b>2020</b> , 49, 484-488	
373	Midostaurin in acute myeloid leukemia: current evidence and practical considerations in routine clinical use. <b>2020</b> , 111, 443-454	0
372	Treatment of older patients with acute myeloid leukemia (AML): revised Canadian consensus guidelines. <b>2017</b> , 7, 30-40	11
371	Older Patients With Acute Myeloid Leukemia: Treatment Challenges and Future Directions. <b>2017</b> , 17, 398-404	21
370	<Editors' Choice> How to improve outcomes of elderly patients with acute myeloid leukemia: era of excitement. <b>2020</b> , 82, 151-160	1
369	[Advancesin FLT3 inhibitors for acute myeloid leukemia]. <b>2019</b> , 40, 787-791	
368	[How I treat FLT3-ITD positive acute myeloid leukemia]. <b>2018</b> , 39, 1-4	0
367	Next generation sequencing guided treatment modulation and prognosis in Acute myeloid leukemia: Case vignettes. <b>2020</b> , 10, 134-144	
366	A new FLT3 inhibitor with two cases: the gilteritinib experience. <b>2021</b> , 11, 271-278	
365	Akute Leukämien. <b>2022</b> , 179-189	
364	PARP1 PARylates and stabilizes STAT5 in FLT3-ITD acute myeloid leukemia and other STAT5-activated cancers. <b>2021</b> , 15, 101283	2
363	New Therapeutic Approaches for Acute Myeloid Leukaemia. 82-89	1
362	Project 2025: Proposals for the Continued Success of Drug Development in Acute Myeloid Leukemia. <b>2021</b> ,	0
361	Management of Acute Myeloid Leukemia: Current Treatment Options and Future Perspectives. <b>2021</b> , 13,	6
360	The challenge of targets and drug discovery using large-scale screening approaches in onco-hematology.. <b>2021</b> ,	
359	Determinants of ten-year overall survival of acute myeloid leukemia: a large national cancer database analysis. <b>2021</b> , 1-7	
358	Pharmacogenomics in solid cancers and hematologic malignancies: Improving personalized drug prescription.. <b>2021</b> ,	0

357	Updates in the Management of Newly Diagnosed Acute Myeloid Leukemia. <b>2021</b> , 19, 1358-1361	
356	Implementing a functional precision medicine tumor board for acute myeloid leukemia. <b>2021</b> ,	8
355	Impact of FLT3 internal tandem duplication and NPM1 mutations in acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation. <b>2021</b> ,	0
354	Hematologic Rare Disease Drug Development. <b>2021</b> , 197-211	
353	Exosomes in the Healthy and Malignant Bone Marrow Microenvironment. <b>2021</b> , 1350, 67-89	1
352	Onkologika. <b>2021</b> , 579-638	
351	Prevention and Treatment of Acute Myeloid Leukemia Relapse after Hematopoietic Stem Cell Transplantation: The State of the Art and Future Perspectives.. <b>2022</b> , 11,	2
350	ELN 2017 classification significantly impacts the risk of early death in acute myeloid leukemia patients receiving intensive induction chemotherapy.. <b>2022</b> , 101, 309-316	1
349	Akute myeloische Leukämie: Therapie im Wandel.	0
348	Dual Targeting of FLT3 and LSD1 Disrupts the MYC Super-Enhancer Complex in Acute Myeloid Leukemia.	
347	Successful treatment of angioinvasive aspergillosis causing diaphragmatic rupture with bowel perforation and cerebral aspergillosis in a patient with FLT3-mutated acute myeloid leukemia: A case report.. <b>2022</b> , 101, e28700	0
346	Evolution of Therapy for Older Patients With Acute Myeloid Leukemia: How Should We Use Currently Available Agents?. <b>2022</b> , 28, 67-72	
345	Follow-up of patients with R/R FLT3-mutation-positive AML treated with gilteritinib in the phase 3 ADMIRAL trial.. <b>2022</b> ,	3
344	Azacitidine to Consolidate and Deepen the Therapeutic Response Achieved by Intensive Induction Treatment in a Young Patient Affected by NPM1mut-AML Who Has Become Ineligible for High-Dose Consolidation.. <b>2022</b> , 1-5	
343	F-box only protein 9 and its role in cancer.. <b>2022</b> , 49, 1537	1
342	Cytogenetic risk classification maintains its prognostic significance in transplanted FLT3-ITD mutated acute myeloid leukemia patients: On behalf of the acute leukemia working party/European society of blood and marrow transplantation.. <b>2022</b> ,	0
341	CARving the Path to Allogeneic CAR T Cell Therapy in Acute Myeloid Leukemia.. <b>2021</b> , 11, 800110	2
340	Everyone is entitled to his or her own opinion but not to their own facts.. <b>2022</b> ,	

339	The Evolving Role of Allogeneic Stem Cell Transplant in the Era of Molecularly Targeted Agents.. <b>2022</b> , 28, 78-84	
338	Selective inhibition of nuclear export: a promising approach in the shifting treatment paradigms for hematological neoplasms.. <b>2022</b> ,	0
337	Emerging FLT3 inhibitors for the treatment of acute myeloid leukemia.. <b>2022</b> , 1-18	1
336	A comparative study of next-generation sequencing and fragment analysis for the detection and allelic ratio determination of FLT3 internal tandem duplication.. <b>2022</b> , 17, 14	0
335	Incorporation of FLT3 Inhibitors Into the Treatment Regimens for FLT3 Mutated Acute Myeloid Leukemia: The Case for Total Therapy.. <b>2022</b> , 28, 14-20	0
334	Impact of mutation on outcomes after venetoclax and azacitidine for patients with treatment-naive acute myeloid leukemia.. <b>2022</b> ,	5
333	Azacitidine maintenance in AML post induction and posttransplant.. <b>2022</b> ,	0
332	Standards for the classification of pathogenicity of somatic variants in cancer (oncogenicity): Joint recommendations of Clinical Genome Resource (ClinGen), Cancer Genomics Consortium (CGC), and Variant Interpretation for Cancer Consortium (VICC).. <b>2022</b> ,	4
331	Improved outcomes among newly diagnosed patients with FMS-like tyrosine kinase 3 internal tandem duplication mutated acute myeloid leukemia treated with contemporary therapy: Revisiting the European LeukemiaNet adverse risk classification.. <b>2022</b> ,	3
330	Gilteritinib clinical activity in relapsed/refractory FLT3 mutated acute myeloid leukemia previously treated with FLT3 inhibitors.. <b>2022</b> ,	3
329	Single-Cell Technologies to Decipher the Immune Microenvironment in Myeloid Neoplasms: Perspectives and Opportunities.. <b>2021</b> , 11, 796477	
328	Maintenance therapy with hypomethylating agents for patients with acute myeloid leukemia in first remission not eligible for allogeneic hematopoietic cell transplantation: A systematic review and meta-analysis.. <b>2021</b> , 113, 106773	0
327	Targeted inhibitors and antibody immunotherapies: Novel therapies for paediatric leukaemia and lymphoma.. <b>2022</b> , 164, 1-17	3
326	Inhibition of BCL2A1 by STAT5 inactivation overcomes resistance to targeted therapies of FLT3-ITD/D835 mutant AML.. <b>2022</b> , 18, 101354	1
325	Tumor Genomic Profiling and Drug Sensitivity Testing for Pediatric Leukemia and Lymphoma Patients.. <b>2022</b> , 27, 123-131	0
324	Combined effect of midostaurin and sphingosine kinase-1 inhibitor on FMS-like tyrosine kinase 3 (FLT3) wild type acute myeloid leukemia cells. <b>2022</b> ,	
323	Frequency and risk factors for thrombosis in acute myeloid leukemia and high-risk myelodysplastic syndromes treated with intensive chemotherapy: a two centers observational study.. <b>2022</b> , 101, 855	0
322	Identification of 2-Aminopyrimidine Derivatives as FLT3 Kinase Inhibitors with High Selectivity over c-KIT.. <b>2022</b> ,	2

321	Differentiation therapy for myeloid malignancies: beyond cytotoxicity. <b>2021</b> , 11, 193	2
320	Efficacy and safety of avapritinib in advanced systemic mastocytosis: interim analysis of the phase 2 PATHFINDER trial. <b>2021</b> ,	10
319	Molecular and genomic landscapes in secondary & therapy related acute myeloid leukemia. <b>2021</b> , 11, 472-497	0
318	Pharmacoeconomic considerations for acute myeloid leukemia pharmacotherapy. <b>2021</b> ,	1
317	The Dynamics of the Labelling Game: An Essay On FLT3 Mutated Acute Myeloid Leukaemia. <b>2022</b> , 121-132	
316	Pharmacoeconomic Analysis of Gilteritinib in the Therapy of Adult Patients with Relapsed/Refractory Acute Myeloid Leukemias with FLT3 Mutation. <b>2022</b> , 15, 85-96	1
315	Analysis of Subset Chimerism for MRD-Detection and Pre-Emptive Treatment in AML.. <b>2022</b> , 12, 841608	1
314	Small Molecule Compounds of Natural Origin Target Cellular Receptors to Inhibit Cancer Development and Progression.. <b>2022</b> , 23,	1
313	Role of Biomarkers in FLT3 AML.. <b>2022</b> , 14,	2
312	Multi-omics reveals mitochondrial metabolism proteins susceptible for drug discovery in AML.. <b>2022</b> ,	1
311	Current Status of CPX-351 Therapy in Acute Myeloid Leukemia and Myelodysplastic Syndrome.. <b>2022</b> ,	
310	Single cell proteogenomic sequencing identifies a relapse-fated AML subclone carrying FLT3 -ITD with CN-LOH at chr13q.	
309	Emerging Targeted Therapy for Specific Genomic Abnormalities in Acute Myeloid Leukemia.. <b>2022</b> , 23,	2
308	European LeukemiaNet 2017 risk stratification for acute myeloid leukemia: validation in a risk-adapted protocol.. <b>2021</b> ,	6
307	Diagnostic Workup of Acute Myeloid Leukemia: What Is Really Necessary? An Italian Survey.. <b>2022</b> , 12, 828072	
306	Increasing Role of Targeted Immunotherapies in the Treatment of AML.. <b>2022</b> , 23,	1
305	Pharmacologic Strategies for Post-Transplant Maintenance in Acute Myeloid Leukemia: It Is Time to Consider!. <b>2022</b> , 14,	0
304	A novel IgG-based FLT3xCD3 bispecific antibody for the treatment of AML and B-ALL.. <b>2022</b> , 10,	2

303	Comparison of mold active triazoles as primary antifungal prophylaxis in patients with newly diagnosed acute myeloid leukemia in the era of molecularly targeted therapies.. <b>2022</b> ,	1
302	Chemotherapy or Allogeneic Stem Cell Transplantation as Salvage Therapy for Patients with Refractory Acute Myeloid Leukemia: A Multicenter Analysis.. <b>2022</b> , 1-11	
301	Translating recent advances in the pathogenesis of acute myeloid leukemia to the clinic.. <b>2022</b> , 36, 259-277	0
300	New Perspectives in Treating Acute Myeloid Leukemia: Driving towards a Patient-Tailored Strategy.. <b>2022</b> , 23,	1
299	Which FLT3 Inhibitor for Treatment of AML?. <b>2022</b> , 23, 359	3
298	Practical tips for managing FLT3 mutated acute myeloid leukemia with midostaurin.. <b>2022</b> , 1-12	0
297	A nonrandomized phase I and biomarker trial of regorafenib in advanced myeloid malignancies.	
296	The proteogenomic subtypes of acute myeloid leukemia.. <b>2022</b> ,	5
295	Refining AML Treatment: The Role of Genetics in Response and Resistance Evaluation to New Agents.. <b>2022</b> , 14,	0
294	RNAi-Mediated Screen of Primary AML Cells Nominates MDM4 as a Therapeutic Target in NK-AML with Mutations.. <b>2022</b> , 11,	1
293	Preclinical and pilot study of type I FLT3 tyrosine kinase inhibitor, crenolanib, with sorafenib in acute myeloid leukemia and FLT3-internal tandem duplication.. <b>2022</b> ,	0
292	Combination strategies to promote sensitivity to cytarabine-induced replication stress in acute myeloid leukemia with and without DNMT3A mutations.. <b>2022</b> ,	0
291	Sorafenib in Combination With Standard Chemotherapy for Children With High Allelic Ratio /ITD+ Acute Myeloid Leukemia: A Report From the Children's Oncology Group Protocol AAML1031.. <b>2022</b> , JCO2101612	2
290	Response Rate, Event-Free Survival, and Overall Survival in Newly Diagnosed Acute Myeloid Leukemia: US Food and Drug Administration Trial-Level and Patient-Level Analyses. <b>2021</b> , JCO2101548	2
289	Impact of diagnostic genetics on remission MRD and transplantation outcomes in older AML patients.. <b>2022</b> ,	4
288	The Multi-Kinase Inhibitor EC-70124 Is a Promising Candidate for the Treatment of FLT3-ITD-Positive Acute Myeloid Leukemia.. <b>2022</b> , 14,	0
287	Point Mutations in the -ITD Region Are Rare but Recurrent Alterations in Adult AML and Associated With Concomitant -PTD.. <b>2022</b> , 12, 862991	0
286	NPM1-mutation-based measurable residual disease assessment after completion of two courses of post-remission therapy is a valuable clinical predictor of the prognosis of acute myeloid leukemia.. <b>2022</b> , 1	0

285	Prediction of Survival with Intensive Chemotherapy in Acute Myeloid Leukemia.. <b>2022,</b>	1
284	Infectious complications of targeted drugs and biotherapies in acute leukemia. Clinical practice guidelines by the European Conference on Infections in Leukemia (ECIL), a joint venture of the European Group for Blood and Marrow Transplantation (EBMT), the European Organization for Research and Treatment of Cancer (EORTC), the International Immunocompromised Host Society	1
283	The Irreversible FLT3 Inhibitor FF-10101 Is Active Against a Diversity of FLT3 Inhibitor Resistance Mechanisms.. <b>2022,</b> OF1-OF11	0
282	Outcomes of second allogeneic stem cell transplantation and anti-relapse strategies in patients with relapsed/refractory AML: a unicentric retrospective analysis.. <b>2022,</b>	0
281	Harnessing the power of sphingolipids: Prospects for acute myeloid leukemia.. <b>2022,</b> 100950	0
280	Consensus guidelines for antifungal prophylaxis in haematological malignancy and haemopoietic stem cell transplantation, 2021.. <b>2021,</b> 51 Suppl 7, 67-88	6
279	Deciphering the Role of Pyrvinium Pamoate in the Generation of Integrated Stress Response and Modulation of Mitochondrial Function in Myeloid Leukemia Cells through Transcriptome Analysis.. <b>2021,</b> 9,	0
278	Clinical utility and real-world application of molecular genetic sequencing in the management of patients with acute myeloid leukemia and myelodysplastic syndromes. <b>2021,</b> 1-10	0
277	Invasive Fungal Infections and Targeted Therapies in Hematological Malignancies.. <b>2021,</b> 7,	3
276	Treatment of AML Relapse After Allo-HCT.. <b>2021,</b> 11, 812207	3
275	Clonal architecture predicts clinical outcomes and drug sensitivity in acute myeloid leukemia.. <b>2021,</b> 12, 7244	1
274	Venetoclax combination therapy in acute myeloid leukemia and myelodysplastic syndromes.. <b>2021,</b> 29,	1
273	Recent Research Progress of Chiral Small Molecular Antitumor-Targeted Drugs Approved by the FDA From 2011 to 2019.. <b>2021,</b> 11, 785855	1
272	FDA-Approved Drugs for Hematological Malignancies-The Last Decade Review.. <b>2021,</b> 14,	4
271	FLT3-ITD allelic ratio and HLF expression predict FLT3 inhibitor efficacy in adult AML. <b>2021,</b> 11, 23565	0
270	Implementation of Clinical Phosphoproteomics and Proteomics for Personalized Medicine.. <b>2022,</b> 2420, 87-106	1
269	A novel algorithmic approach to generate consensus treatment guidelines in adult acute myeloid leukaemia.. <b>2021,</b>	0
268	What to use to treat AML: the role of emerging therapies. <b>2021,</b> 2021, 16-23	2

- 267 Integrated RNAi screening identifies the NEDDylation pathway as a synergistic partner of azacytidine in acute myeloid leukemia. **2021**, 11, 23280 ○
- 266 Synthesis and biological evaluation of novel 5,6-dihydrobenzo[h]quinazoline derivatives as FLT3 inhibitors. **2021**,
- 265 Interim results from a postmarketing surveillance study of patients with FLT3-mutated relapsed/refractory AML treated with the FLT3 inhibitor gilteritinib in Japan.. **2022**, ○
- 264 C/EBP $\beta$  confers dependence to fatty acid anabolic pathways and vulnerability to lipid oxidative stress in FLT3-mutant leukemia. ○
- 263 Transplant Outcomes After CPX-351 vs 7+3 in Older Adults With Newly Diagnosed High-risk and/or Secondary AML.. **2022**, 1
- 262 Targeting the lysine-specific demethylase 1 rewires kinase networks and primes leukemia cells for kinase inhibitor treatment.. **2022**, 15, eabl7989 4
- 261 Comparative efficacy and safety of eleven induction chemotherapy regimens for young adult patients with newly diagnosed acute myeloid leukemia: a network meta-analysis.. **2022**, 1
- 260 Pediatric Acute Myeloid Leukemia Enters the Molecularly Targeted Era Via FLT3 Inhibition.. **2022**, JCO2200499
- 259 Comparison of the impact of two post-remission therapy regimens on cardiac events in acute myeloid leukemia patients undergoing allogeneic hematopoietic stem cell transplantation.. **2022**, 1 ○
- 258 Data\_Sheet\_1.docx. **2020**,
- 257 FLT3-inhibitor therapy for prevention and treatment of relapse after allogeneic hematopoietic cell transplantation.. **2022**, 1 ○
- 256 ABCB1 as a potential beneficial target of midostaurin in acute myeloid leukemia.. **2022**, 150, 112962 ○
- 255 Shall We Dance: Evolving Partnerships of Targeted Therapies for AML.. **2022**,
- 254 Upregulation of hsa-miR-625-5p Inhibits Invasion of Acute Myeloid Leukemia Cancer Cells through ILK/AKT Pathway.. **2022**, 24, 76-84
- 253 Efficacy and Safety of Midostaurin Combined with Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation. **2022**, 15, 167-175
- 252 Advancing the standard: venetoclax combined with intensive induction and consolidation therapy for acute myeloid leukemia.. **2022**, 13, 20406207221093964 ○
- 251 Midostaurin plus intensive chemotherapy for younger and older Patients with AML and FLT3 internal tandem duplications.. **2022**, ○
- 250 Standards der kurativen Systemtherapie der akuten myeloischen Leukämie.



249	mutations in acute myeloid leukemia: a review focusing on clinically applicable drugs.. <b>2022</b> , 57, 32-36	1
248	High Expression of DC-STAMP Gene Predicts Adverse Outcomes in AML.. <b>2022</b> , 13, 876689	0
247	A Rare Case of Midostaurin-Associated Sweet's Syndrome.. <b>2022</b> , 2022, 1099005	1
246	The EHA Research Roadmap: Hematopoietic Stem Cells and Allogeneic Transplantation.. <b>2022</b> , 6, e0714	0
245	Venetoclax combined with induction chemotherapy in patients with newly diagnosed acute myeloid leukaemia: a post-hoc, propensity score-matched, cohort study.. <b>2022</b> , 9, e350-e360	2
244	Antifungal prophylaxis in adult patients with acute myeloid leukaemia treated with novel targeted therapies: a systematic review and expert consensus recommendation from the European Hematology Association.. <b>2022</b> , 9, e361-e373	1
243	Target Therapy for Extramedullary Relapse of -ITD Acute Myeloid Leukemia: Emerging Data from the Field.. <b>2022</b> , 14,	0
242	The dual role of autophagy in acute myeloid leukemia.. <b>2022</b> , 15, 51	1
241	Hypomethylating agent and venetoclax with FLT3 inhibitor "triplet" therapy in older/unfit patients with FLT3 mutated AML.. <b>2022</b> , 12, 77	3
240	FLT3-targeted treatment for acute myeloid leukemia.. <b>2022</b> ,	0
239	Cancers of the Blood. <b>2022</b> , 67-131	
238	Venetoclax Combined with FLAG-IDA Induction and Consolidation in Newly Diagnosed Acute Myeloid Leukemia.. <b>2022</b> ,	3
237	Impact of treatment intensity on infectious complications in patients with acute myeloid leukemia.. <b>2022</b> ,	
236	The FLT3 Y842D mutation may be highly sensitive to midostaurin: a case report.. <b>2022</b> , 50, 3000605221097774	0
235	FLT3 Inhibitors for Acute Myeloid Leukemia: Successes, Defeats, and Emerging Paradigms.	0
234	Spatially Constrained Gene Regulation Identifies Key Genetic Contributions of Preeclampsia, Hypertension and Proteinuria.	
233	Carbohydrate-based drugs launched during 2000-2021. <b>2022</b> ,	4
232	Molecular Classification and Overcoming Therapy Resistance for Acute Myeloid Leukemia with Adverse Genetic Factors. <b>2022</b> , 23, 5950	1

231	Digital Droplet PCR in Hematologic Malignancies: A New Useful Molecular Tool. <b>2022</b> , 12, 1305	0
230	Contemporary Approach to Acute Myeloid Leukemia Therapy in 2022. <b>2022</b> , 1-16	1
229	High Incidence of Invasive Fungal Diseases in Patients with FLT3-Mutated AML Treated with Midostaurin: Results of a Multicenter Observational SEIFEM Study. <b>2022</b> , 8, 583	
228	Clinical outcomes in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia treated with gilteritinib who received prior midostaurin or sorafenib. <b>2022</b> , 12,	1
227	A key role of the WEE1-CDK1 axis in mediating TKI-therapy resistance in FLT3-ITD positive acute myeloid leukemia patients.	
226	Older Patients with Acute Myeloid Leukemia Deserve Individualized Treatment.	0
225	New Therapeutic Strategies for Adult Acute Myeloid Leukemia. <b>2022</b> , 14, 2806	0
224	Application of precision medicine in clinical routine in haematology—challenges and opportunities.	1
223	Acute and chronic leukemias. <b>2023</b> , 403-411	
222	Resistance to targeted therapies: delving into FLT3 and IDH. <b>2022</b> , 12,	1
221	Vaccination Therapy for Acute Myeloid Leukemia: Where Do We Stand?. <b>2022</b> , 14, 2994	2
220	Evaluation of drug-drug interactions between midostaurin and strong CYP3A4 inhibitors in patients with FLT-3-mutated acute myeloid leukemia (AML).	2
219	Antibody-based therapy for acute myeloid leukemia: a review of phase 2 and 3 trials.	
218	High-Risk Acute Myeloid Leukemia: A Pediatric Prospective. <b>2022</b> , 10, 1405	
217	Comprehensive Validation of Diagnostic Next-Generation Sequencing Panels for Acute Myeloid Leukemia Patients. <b>2022</b> ,	
216	Adjunction of a fish oil emulsion to cytarabine and daunorubicin induction chemotherapy in high-risk AML. <b>2022</b> , 12,	1
215	How Genetics Can Drive Initial Therapy Choices for Older Patients with Acute Myeloid Leukemia.	1
214	Re-induction versus Salvage for D14-residual Acute Myeloid Leukemia: A Retrospective multi-center Study. <b>2022</b> , 106902	1

213	Gilteritinib monotherapy for relapsed/refractory FLT3 mutated acute myeloid leukemia: a real-world, multi-center, matched analysis.	0
212	Molecular-Targeted Therapy of Pediatric Acute Myeloid Leukemia. <b>2022</b> , 27, 3911	
211	Identify Multiple Gene-Drug Common Modules Via Constrained Graph Matching. <b>2022</b> , 1-12	
210	Characteristics and outcome of patients with acute myeloid leukemia and trisomy 4.	
209	The Utility of Multistate Models: A Flexible Framework for Time-to-Event Data.	0
208	Depth of Response to Intensive Chemotherapy Has Significant Prognostic Value among Acute Myeloid Leukemia (AML) Patients Undergoing Allogeneic Hematopoietic Stem-Cell Transplantation with Intermediate or Adverse Risk at Diagnosis Compared to At-Risk Group According to European Leukemia Net 2017 Risk Stratification. <b>2022</b> , 14, 3199	1
207	Frugal alignment-free identification of FLT3-internal tandem duplications with FiLT3r.	
206	AACR Project GENIE: 100,000 cases and beyond.	2
205	Drug Resistance Mechanisms of Acute Myeloid Leukemia Stem Cells. 12,	0
204	Novel Mechanisms for Post-Transplant Maintenance Therapy in Acute Myeloid Leukemia. 12,	
203	Development of a bispecific Antibody Drug Conjugate targeting CD7 and CD33 to treat Acute Myeloid Leukaemia.	
202	Targeting Acute Myeloid Leukemia with Venetoclax; Biomarkers for Sensitivity and Rationale for Venetoclax-Based Combination Therapies. <b>2022</b> , 14, 3456	3
201	Revealing molecular architecture of FLT3 internal tandem duplication: Development and clinical validation of a web-based application to generate accurate nomenclature.	
200	In vivo genome-wide CRISPR screening in murine acute myeloid leukemia uncovers microenvironmental dependencies.	0
199	Retrospective analysis of three induction chemotherapy regimens in acute myeloid leukemia including CPX-351, cytarabine/daunorubicin with and without the addition of cladribine. 1-7	0
198	Quizartinib prolongs survival of newly diagnosed FLT3-ITD-mutated AML.	
197	â€œLippingâ€œThe Story: FLT3-Mutated Acute Myeloid Leukemia and the Evolving Role of FLT3 Inhibitors. <b>2022</b> , 14, 3398	2
196	Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia.	4

195	Diagnosis and Management of AML in Adults: 2022 ELN Recommendations from an International Expert Panel.	60
194	Synthesis and biological evaluation of 4-(4-aminophenyl)-6-methylisoxazolo[3,4-b] pyridin-3-amine covalent inhibitors as potential agents for the treatment of acute myeloid leukemia. <b>2022</b> , 70, 116937	0
193	Integrative analysis of drug response and clinical outcome in acute myeloid leukemia. <b>2022</b> ,	4
192	A Systems Biology- and Machine Learning-Based Study to Unravel Potential Therapeutic Mechanisms of Midostaurin as a Multitarget Therapy on FLT3-Mutated AML. <b>2022</b> , 2, 375-397	
191	Erstlinientherapie intensiv-therapierbarer AML-Patient*innen. <b>2022</b> , 25, 16-21	
190	Design of the VIALE-M phase III trial of venetoclax and oral azacitidine maintenance therapy in acute myeloid leukemia.	0
189	Adverse impact of a high allelic burden FLT3-ITD mutation on allogeneic hematopoietic stem cell transplantation in patients with cytogenetically normal AML.	0
188	Clinical Impact of Measurable Residual Disease in Acute Myeloid Leukemia. <b>2022</b> , 14, 3634	1
187	In Pursuit of Genetic Prognostic Factors and Treatment Approaches in Secondary Acute Myeloid LeukemiaâA Narrative Review of Current Knowledge. <b>2022</b> , 11, 4283	
186	Modulation of BCL-2 in both T Cells and Tumor Cells to Enhance Chimeric Antigen Receptor T cell Immunotherapy against Cancer.	1
185	Proteomic and Phosphoproteomic Landscapes of Acute Myeloid Leukemia.	2
184	NF- $\kappa$ B: A Druggable Target in Acute Myeloid Leukemia. <b>2022</b> , 14, 3557	0
183	Function and Clinical Significance of Circular RNAs in Thyroid Cancer. 9,	0
182	Time from diagnosis to treatment is associated with survival in patients with acute myeloid leukaemia: An analysis of 55 985 patients from the National Cancer Database.	
181	Miyeloid Lemi Tedavisinde Etkili Bir Bâolan Midostaurinin Molekâer Kenetlenme âlâasâ	
180	Management of older patients with frailty and acute myeloid leukaemia: A British Society for Haematology good practice paper.	
179	Mechanisms of myeloid leukemogenesis: Current perspectives and therapeutic objectives. <b>2022</b> , 100996	0
178	Unified classification and risk-stratification in Acute Myeloid Leukemia. <b>2022</b> , 13,	4

177	Single cell genomics in AML: extending the frontiers of AML research.	1
176	Midostaurin as the Most Likely Cause of Bilateral Adrenal Masses in a Patient with Acute Myeloid Leukemia.	0
175	Phase 3 Trial of Gilteritinib Plus Azacitidine Vs Azacitidine for Newly Diagnosed FLT3mut+ AML Ineligible for Intensive Chemotherapy.	4
174	Sorafenib maintenance after hematopoietic stem cell transplantation improves outcome of FLT3-ITD-mutated acute myeloid leukemia.	0
173	Pre-transplant FLT3-ITD MRD assessed by high-sensitivity PCR-NGS determines post-transplant clinical outcome.	2
172	Precision Medicine in Myeloid Malignancies: Hype or Hope?.	1
171	Pharmacogenomic profiling of pediatric acute myeloid leukemia to identify therapeutic vulnerabilities and inform functional precision medicine.	1
170	Targeting SAMHD1 with hydroxyurea in first-line cytarabine-based therapy of newly diagnosed acute myeloid leukaemia: Results from the HEAT-AML trial.	0
169	Are Pivotal Clinical Trials for Drugs Approved for Leukemias and Multiple Myeloma Representative of the Population at Risk?.	0
168	Adolescents and young adults (AYA) with acute myeloid leukemia (AML): real-world long-term results and age-specific outcomes. 1-10	
167	Genomic landscape of patients with FLT3-mutated acute myeloid leukemia (AML) treated within the CALGB 10603/RATIFY trial. <b>2022</b> , 36, 2218-2227	0
166	A novel fatty acid metabolism-related signature identifies features of the tumor microenvironment and predicts clinical outcome in acute myeloid leukemia. <b>2022</b> , 21,	1
165	Advances in the pharmacological management of acute myeloid leukemia in adults.	0
164	Chasing leukemia differentiation through induction therapy, relapse and transplantation. <b>2022</b> , 101000	
163	Functional Drug Screening of Small Molecule Inhibitors of Epigenetic Modifiers in Refractory AML Patients. <b>2022</b> , 14, 4094	
162	Developments and challenges of FLT3 inhibitors in acute myeloid leukemia. 12,	1
161	Real-world clinical outcomes with enasidenib in relapsed or refractory acute myeloid leukemia. <b>2022</b> , 122, 106946	0
160	Synthesis and biological activity of bisindole derivatives as novel MARK4 inhibitors. <b>2022</b> , 6, 100076	0

- 159 FLT3?????????????????????. **2022**, ○
- 158 Management of Acute Myeloid Leukemia: A Review for General Practitioners in Oncology. **2022**, 29, 6245-6259○
- 157 Clinically relevant variation in FLT3-ITD quantitation as a result of PCR cycle number and ITD insertion size. **2022**, 1
- 156 Oral Antineoplastics in Acute Myeloid Leukemia: A Comprehensive Review. **2022**, ○
- 155 Akute Myeloische Leukämien âUpdate 2022. **2022**, 147, 1108-1114 ○
- 154 A Focus on Intermediate-Risk Acute Myeloid Leukemia: Sub-Classification Updates and Therapeutic Challenges. **2022**, 14, 4166 ○
- 153 Differential prognostic impact of RUNX1 mutations according to frontline therapy in patients with acute myeloid leukemia. ○
- 152 Impact on Outcome of Minimal Residual Disease after Hematopoietic Stem Cell Transplantation with Fludarabine, Amsacrine, and Cytosine Arabinoside-Busulfan Conditioning: A Retrospective Monocentric Study. **2022**, 1
- 151 Protein tyrosine kinase 2b inhibition reverts niche-associated resistance to tyrosine kinase inhibitors in AML. **2022**, 36, 2418-2429 ○
- 150 Prognostic Relevance of NPM1 and FLT3 Mutations in Acute Myeloid Leukaemia, Longterm Follow-Upâ Single Center Experience. **2022**, 14, 4716 ○
- 149 The research progress of targeted therapy in acute myeloid leukemia based on bibliometric analysis. 12, ○
- 148 How I Treat TP53-Mutated Acute Myeloid Leukemia and Myelodysplastic Syndromes. **2022**, 14, 4519 2
- 147 Molecular Diagnostic Testing for Hematopoietic Neoplasms. **2022**, 42, 325-347 ○
- 146 Integrative analysis identifies an older female-linked AML patient group with better risk in ECOG-ACRIN Cancer Research Groupâ clinical trial E3999. **2022**, 12, ○
- 145 A nomogram using cytogenetics, TP53, and NPM1 mutational status can predict responses to induction chemotherapy in AML. 1-4 ○
- 144 A systematic review of economic evaluations for the pharmaceutical treatment of chronic lymphocytic leukemia and acute myeloid leukemia. **2022**, 15, 833-847 ○
- 143 A New Dancing Partner for Venetoclax: Gilteritinib. ○
- 142 Impact of Genetic Polymorphisms and Biomarkers on the Effectiveness and Toxicity of Treatment of Chronic Myeloid Leukemia and Acute Myeloid Leukemia. **2022**, 12, 1607 ○

- 141 Updates on the Management of Acute Myeloid Leukemia. **2022**, 14, 4756 ○
- 140 FLT3 Inhibitors as Maintenance Therapy after Allogeneic Stem-Cell Transplantation. Volume 12, 137-147 1
- 139 Overcoming Resistance: FLT3 Inhibitors Past, Present, Future and the Challenge of Cure. **2022**, 14, 4315 1
- 138 Outcomes of Induction Therapy in Patients With Acute Myeloid Leukemia During the COVID-19 Pandemic: A Retrospective Study From a Tertiary Cancer Center. **2022**, ○
- 137 Treatment options for acute myeloid leukemia patients aged <math>\leq 60</math> years. 12, ○
- 136 Thymic adenocarcinoma presenting as an incidental mediastinal mass. **2022**, 17, ○
- 135 Contemporary evaluation of acute myeloid leukemia patients with long-term survival exceeding 5 years. ○
- 134 The Cross-Talk between Epigenetic Gene Regulation and Signaling Pathways Regulates Cancer Pathogenesis. **2022**, 427-472 ○
- 133 Current strategies for the treatment of acute myeloid leukemia. **2022**, 75, 11-14 ○
- 132 Pre-MEASURE: FLT3-ITD and mutated NPM1 measurable residual disease before allogeneic transplant in adults with AML in first remission. ○
- 131 Clinical Efficacies of FLT3 Inhibitors in Patients with Acute Myeloid Leukemia. **2022**, 23, 12708 ○
- 130 Clinical application of molecular genetics in acute myeloid leukemia. 1-6 ○
- 129 Real world molecular characterisation and clonal evolution of acute myeloid leukaemia reveals therapeutic opportunities and challenges. **2022**, ○
- 128 The m6A reader IGF2BP2 regulates glutamine metabolism and represents a therapeutic target in acute myeloid leukemia. **2022**, ○
- 127 Frugal alignment-free identification of FLT3-internal tandem duplications with FiLT3r. **2022**, 23, ○
- 126 Stellenwert der allogenen Stammzelltransplantation bei AML. **2022**, 25, 10-17 ○
- 125 Influences of rare protein-coding genetic variants on the human plasma proteome in 50,829 UK Biobank participants. ○
- 124 Prognostic Value of FLT3-Internal Tandem Duplication Residual Disease in Acute Myeloid Leukemia. ○

- 123 Clinical Outcomes of Acute Myeloid Leukemia Patients Harboring the RUNX1 Mutation: Is It Still an Unfavorable Prognosis? A Cohort Study and Meta-Analysis. **2022**, 14, 5239 1
- 122 Consolidation chemotherapy in AML: Are we playing with a full deck of cards?. **2022**, 101408 0
- 121 Feasibility of autologous peripheral blood stem cell mobilization and harvest in adult patients with FLT3-mutated acute myeloid leukemia receiving chemotherapy combined with midostaurin: a single-center experience. 0
- 120 A phase Ib trial of mivavotinib (TAK-659), a dual SYK/FLT3 inhibitor, in patients with relapsed/refractory acute myeloid leukemia. 0
- 119 Use of endpoints in phase III randomized controlled trials for acute myeloid leukemia over the last 15 years: a systematic review. 1-10 0
- 118 Acute Myeloid Leukemia in Adults: Mast Cell Leukemia and Other Mast Cell Neoplasms. 1-21 0
- 117 The Cup Runneth Over: Treatment Strategies for Newly Diagnosed Acute Myeloid Leukemia. 0
- 116 Virtual screening and repurposing of approved drugs targeting homoserine dehydrogenase from *Paracoccidioides brasiliensis*. **2022**, 28, 0
- 115 How Can We Intervene to Mitigate Post-transplantation Relapse in AML? Strategies to Mitigate Post-transplantation Relapse in AML. **2022**, 101411 0
- 114 Molecular targets for the treatment of AML in the forthcoming 5th World Health Organization Classification of Haematolymphoid Tumours. 1-14 0
- 113 Resistance to targeted therapies in acute myeloid leukemia. 0
- 112 Rhodium catalysed intramolecular benzannulation for the formation of tetracyclic carbazoles. 1
- 111 Therapeutic Options in Myelodysplastic Syndromes: Established and Emerging Therapies. 71-81 0
- 110 Significance of Gene Diagnosis in Acute Myeloid Leukemia with the Emergence of New Molecular Target Drug Treatment. **2022**, 89, 470-478 0
- 109 Transcriptomics of acute myeloid leukaemia core bone marrow biopsies reveals distinct therapy response-specific osteo-mesenchymal profiles. 0
- 108 Current and emerging pharmacotherapy for the treatment of childhood acute myeloid leukemia. 1-11 0
- 107 SOHO State of the Art Updates and Next Questions | The Role of Maintenance Therapy in Acute Myeloid Leukemia. **2022**, 0
- 106 Measurable residual disease detected by flow cytometry independently predicts prognoses of NPM1-mutated acute myeloid leukemia. 0



105	Gilteritinib activity in refractory or relapsed FLT3-mutated acute myeloid leukemia patients previously treated by intensive chemotherapy and midostaurin: a study from the French AML Intergroup ALFA/FILO.	0
104	Protein Kinase C (PKC) Isozymes as Diagnostic and Prognostic Biomarkers and Therapeutic Targets for Cancer. <b>2022</b> , 14, 5425	0
103	Real-life challenges using personalized prognostic scoring systems in acute myeloid leukemia.	0
102	Leukoreductive response to the combination of sorafenib and chemotherapy in hyperleukocytosis of FLT3-ITD mutated pediatric AML. 10,	0
101	A randomized phase 2 trial of nintedanib and low-dose cytarabine in elderly patients with acute myeloid leukemia ineligible for intensive chemotherapy.	0
100	Molecular Signatures in Acute Myeloid Leukemia: From Diagnosis to Targeted Therapy and Drug Repositioning. <b>2022</b> ,	0
99	Advances and Future Goals in Acute Myeloid Leukaemia Therapy. <b>2022</b> , 18, 130	0
98	Distinct mutational and clinicopathologic profiles characterize acute myeloid leukemia with cup-like nuclei. <b>2023</b> , 124, 106995	0
97	Successful Pre- and Post-transplant Administration of Gilteritinib in a Patient with Relapsed and Refractory Acute Myeloid Leukemia Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation. <b>2023</b> ,	0
96	Heterogeneous nuclear ribonucleoprotein K is overexpressed in acute myeloid leukemia and causes myeloproliferation in mice via altered Runx1 splicing. <b>2022</b> , 4,	1
95	Moving toward individualized target-based therapies in acute myeloid leukemia. <b>2022</b> ,	1
94	19S Proteasome Subunits as Oncogenes and Prognostic Biomarkers in FLT3-Mutated Acute Myeloid Leukemia (AML). <b>2022</b> , 23, 14586	0
93	CLINICAL FEATURES OF FLT3 MUTATIONS IN ACUTE MYELOID LEUKEMIA CASES AND THE ROLE OF FLT3 INHIBITORS IN THE TREATMENT OF ACUTE MYELOID LEUKEMIA: A SINGLE CENTER EXPERIENCE.	0
92	Heterogeneity of Patient-Derived Acute Myeloid Leukemia Cells Subjected to SYK In Vitro Inhibition. <b>2022</b> , 23, 14706	0
91	FLT3 inhibitors as maintenance therapy post allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia patients with FLT3 mutations: A meta-analysis.	0
90	Therapeutic Targeting of FLT3 in Acute Myeloid Leukemia: Current Status and Novel Approaches. Volume 15, 1449-1478	0
89	Role of Biomarkers in the Management of Acute Myeloid Leukemia. <b>2022</b> , 23, 14543	0
88	Greater expectations: meeting clinical needs through broad and rapid genomic testing. <b>2022</b> ,	0

- 87 Allosteric SHP2 Inhibition Increases Apoptotic Dependency on BCL2 and Synergizes with Venetoclax in FLT3-andKIT-Mutant AML. ○
- 86 Leucemie mieloidi acute. **2022**, 24, 1-11 ○
- 85 The evolution of targeted therapy in pediatric AML: gemtuzumab ozogamicin, FLT3/IDH/BCL2 inhibitors, and other therapies. **2022**, 2022, 603-610 ○
- 84 Optimizing outcomes in secondary AML. **2022**, 2022, 23-29 ○
- 83 Allogeneic stem cell transplant improves survival after first- or second-line therapy in TP53-mutated acute myeloid leukemia: Results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND).. ○
- 82 Proteogenomic analysis of acute myeloid leukemia associates relapsed disease with reprogrammed energy metabolism both in adults and children. ○
- 81 A key role of the WEE1-CDK1 axis in mediating TKI-therapy resistance in FLT3-ITD positive acute myeloid leukemia patients. ○
- 80 Anti-tumor effect of antibody drug conjugate ASP1235 targeting Fms-like tyrosine kinase 3 with venetoclax plus azacitidine in an acute myeloid leukemia xenograft mouse model. **2022**, 13, 1359-1368 ○
- 79 Real-World Efficacy Outcomes of FLT3-ITD Acute Myeloid Leukemia Patients Treated with Midostaurin in Combination with Intensive Induction. **2022**, ○
- 78 Optimization of tyrosine kinase inhibitor-loaded gold nanoparticles for stimuli-triggered antileukemic drug release. ○
- 77 Outcomes in Patients With FLT3-Mutated R/R AML Who Underwent Transplantation in the Phase 3 ADMIRAL Trial of Gilteritinib Versus Salvage Chemotherapy. **2022**, ○
- 76 Electrostatic anti-CD33-antibody-protamine nanocarriers as platform for a targeted treatment of acute myeloid leukemia. **2022**, 15, ○
- 75 Biallelic TET2 mutation sensitizes to 5-azacitidine in acute myeloid leukemia. ○
- 74 Novel investigational approaches for high-risk genetic subsets of AML: TP53, KMT2A, FLT3. **2022**, 2022, 15-22 ○
- 73 Novel benzo chromene derivatives: design, synthesis, molecular docking, cell cycle arrest, and apoptosis induction in human acute myeloid leukemia HL-60 cells. **2023**, 38, 405-422 1
- 72 Transplant in AML with measurable residual disease: proceed or defer?. **2022**, 2022, 528-533 ○
- 71 Microenvironmental CXCL12 deletion enhances Flt3-ITD acute myeloid leukemia stem cell response to therapy by reducing p38 MAPK signaling. ○
- 70 Posttransplant gilteritinib maintenance therapy for pediatric acute myeloid leukemia with myelodysplasia-related changes with FLT3- internal tandem duplication. ○

69	Evidence-Based Minireview: Clinical utilization of panel-based molecular testing for patients with AML. <b>2022</b> , 2022, 30-33	0
68	Layered immunity and layered leukemogenicity: Developmentally restricted mechanisms of pediatric leukemia initiation.	0
67	Dihydropyrimidinase-like 2 can serve as a novel therapeutic target and prognostic biomarker in acute myeloid leukemia.	0
66	FMS-Like Tyrosine Kinase 3 Inhibitors in the Treatment of Acute Myeloid Leukemia: An Update on the Emerging Evidence and Safety Profile. Volume 16, 31-45	0
65	Mutational analysis of DNMT3A improves the prognostic stratification of patients with acute myeloid leukemia.	0
64	Classification of FLT3 Inhibitors and SAR Analysis by Machine Learning Methods.	0
63	A Phase II Study of Combination Daunorubicin, Cytarabine (Ara-c) and Nilotinib ( TAsigna ) ( DATA ) in Patients Newly Diagnosed with Acute Myeloid Leukemia with KIT Expression.	1
62	Acute myeloid leukemia: 2023 update on diagnosis, risk-stratification, and management.	2
61	Acute myeloid leukemia: challenges for diagnosis and treatment in Latin America. <b>2023</b> , 28,	0
60	Design, synthesis, and evaluation of pyrido.[3,4-b]pyrazin-2(1H)-one derivatives as potent FLT3 inhibitors. <b>2023</b> , 79, 117155	0
59	Genomics and Diagnostics in Acute Myeloid Leukaemia. <b>2019</b> , 161-185	0
58	Evaluation of morphological, clinical, and prognostic significance of nucleophosmin gene mutation in de novo acute myeloid leukemia: A retrospective study. <b>2022</b> , 2, 102	0
57	Different treatment strategies versus a common standard arm (CSA) in patients with newly diagnosed AML over the age of 60 years: a randomized German inter-group study.	0
56	Prediction of survival with lower intensity therapy among older patients with acute myeloid leukemia.	1
55	Targeting Proliferation Signals and the Cell Cycle Machinery in Acute Leukemias: Novel Molecules on the Horizon. <b>2023</b> , 28, 1224	0
54	Experimental drugs in clinical trials for acute myeloid leukemia: innovations, trends, and opportunities. 1-15	0
53	Role of allotransplantation in older patients with AML. <b>2023</b> , 141, 217-218	0
52	Codelivery of BCL2 and MCL1 Inhibitors Enabled by Phenylboronic Acid-Functionalized Polypeptide Nanovehicles for Synergetic and Potent Therapy of Acute Myeloid Leukemia. 2204866	0

- 51 Sitravatinib as a potent FLT3 inhibitor can overcome gilteritinib resistance in acute myeloid leukemia. **2023**, 11, ○
- 50 A novel signature of cuproptosis-related lncRNAs predicts prognosis in glioma: Evidence from bioinformatic analysis and experiments. 14, ○
- 49 Proteomic Characterization of Acute Myeloid Leukemia for Precision Medicine. **2023**, 22, 100517 ○
- 48 Dermatologic complications in transplantation and cellular therapy for acute leukemia. **2023**, 36, 101464 ○
- 47 Allogeneic hematopoietic cell transplantation in acute myeloid leukemia. **2023**, 36, 101466 ○
- 46 Targeting FLT3 Mutation in Acute Myeloid Leukemia: Current Strategies and Future Directions. **2023**, 15, 2312 ○
- 45 MicroRNA, mRNA, and Proteomics Biomarkers and Therapeutic Targets for Improving Lung Cancer Treatment Outcomes. **2023**, 15, 2294 ○
- 44 Epigenomic machinery regulating pediatric AML: Clonal expansion mechanisms, therapies, and future perspectives. **2023**, 92, 84-101 ○
- 43 Drug-drug interactions associated with FLT3 inhibitors for acute myeloblastic leukemia: current landscape. **2023**, 16, 133-148 ○
- 42 Update on current treatments for adult acute myeloid leukemia: to treat acute myeloid leukemia intensively or non-intensively? That is the question. **2023**, 108, 342-352 ○
- 41 New drugs before, during, and after hematopoietic stem cell transplantation for patients with acute myeloid leukemia. **2023**, 108, 321-341 1
- 40 Leukemic stem cells and therapy resistance in acute myeloid leukemia. **2023**, 108, 353-366 ○
- 39 The clinical impact of the molecular landscape of acute myeloid leukemia. **2023**, 108, 308-320 1
- 38 Hämatologische Neoplasien und solide Tumore. **2022**, 85-151 ○
- 37 Cre recombinase expression cooperates with homozygous FLT3 internal tandem duplication knockin mouse model to induce acute myeloid leukemia. **2023**, 37, 741-750 ○
- 36 TP53 in AML and MDS: The new (old) kid on the block. **2023**, 101055 ○
- 35 Survival of TP53-mutated acute myeloid leukemia patients receiving allogeneic stem cell transplantation after first induction or salvage therapy: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND). **2023**, 37, 799-806 ○
- 34 An Update on FLT3 in Acute Myeloid Leukemia: Pathophysiology and Therapeutic Landscape. **2023**, 25, 369-378 ○

- 33 A Novel Fatty Acid Metabolism-Associated Risk Model for Prognosis Prediction in Acute Myeloid Leukaemia. **2023**, 30, 2524-2542 ○
- 32 Clinical Implications of the FLT3-ITD Allelic Ratio in Acute Myeloid Leukemia in the Context of an Allogeneic Stem Cell Transplantation. **2023**, 15, 1312 ○
- 31 Retinoic acid and proteotoxic stress induce AML cell death overcoming stromal cell protection. ○
- 30 Current and Emerging Techniques for Diagnosis and MRD Detection in AML: A Comprehensive Narrative Review. **2023**, 15, 1362 ○
- 29 Outcome prediction by the 2022 European LeukemiaNet genetic-risk classification for adults with acute myeloid leukemia: an Alliance study. **2023**, 37, 788-798 ○
- 28 Evolving Risk Classifications in AML in a Real-Life Scenario: After Changes upon Changes, Is It More and More Adverse?. **2023**, 15, 1425 ○
- 27 Prise en charge des LAM chez les sujets âgés. **2023**, 110, 424-432 ○
- 26 Validation of the prognostic significance of the 2022 European LeukemiaNet risk stratification system in intensive chemotherapy treated aged 18 to 65 years patients with de novo acute myeloid leukemia. **2023**, 98, 760-769 1
- 25 Targeting Measurable Residual Disease (MRD) in Acute Myeloid Leukemia (AML): Moving beyond Prognostication. **2023**, 24, 4790 ○
- 24 Management of Newly Diagnosed Acute Myeloid Leukemia in Older Adults. ○
- 23 Non-intensive acute myeloid leukemia therapies for older patients. **2023**, 16, 171-180 ○
- 22 Molecularly Targeted Therapy in Acute Myeloid Leukemia: Current Treatment Landscape and Mechanisms of Response and Resistance. **2023**, 15, 1617 ○
- 21 DNA Sequencing to Detect Residual Disease in Adults With Acute Myeloid Leukemia Prior to Hematopoietic Cell Transplant. **2023**, 329, 745 ○
- 20 Hepatotoxicity of Small Molecule Protein Kinase Inhibitors for Cancer. **2023**, 15, 1766 ○
- 19 Identifying prognostic gene panels in acute myeloid leukemia. **2023**, 16, 277-287 ○
- 18 An Updated Overview of the Role of CYP450 during Xenobiotic Metabolization in Regulating the Acute Myeloid Leukemia Microenvironment. **2023**, 24, 6031 ○
- 17 Prediction model for drug response of acute myeloid leukemia patients. **2023**, 7, ○
- 16 Recent advances in targeted therapies in acute myeloid leukemia. **2023**, 16, ○

- 15 Status of FLT3-ITD Analysis in Korea (2021). **2023**, 13, 72-77
- 14 Neue Therapieoptionen bei der Akuten Myeloischen Leukämie. **2023**, 148, 451-458
- 13 PROTACing oncoproteins: targeted protein degradation for cancer therapy. **2023**, 22,
- 12 The Goldilocks Dilemma in AML: Too Young and Fit, but Not Young and Fit Enough. **2023**,
- 11 Overcoming relapse: prophylactic or pre-emptive use of azacitidine or FLT3 inhibitors after allogeneic transplantation for AML or MDS.
- 10 A review of treatment options employed in relapsed/refractory AML. **2023**, 28,
- 9 CD33 BiTE molecule-mediated immune synapse formation and subsequent T-cell activation is determined by the expression profile of activating and inhibitory checkpoint molecules on AML cells.
- 8 Validation and refinement of the 2022 European LeukemiaNet genetic risk stratification of acute myeloid leukemia.
- 7 Therapeutic Targets in Myelodysplastic Neoplasms: Beyond Hypomethylating Agents.
- 6 Revisiting the prognostic role of FLT3 mutations in acute myelogenous leukemia. 1-7
- 5 Integrated bioinformatic analysis of mitochondrial metabolism-related genes in acute myeloid leukemia. 14,
- 4 Targeted therapy. **2023**, 205-411
- 3 Single-Cell Next-Generation Sequencing to Monitor Hematopoietic Stem-Cell Transplantation: Current Applications and Future Perspectives. **2023**, 15, 2477
- 2 In silico predicted compound targeting the IQGAP1-GRD domain selectively inhibits growth of human acute myeloid leukemia.
- 1 Multifunctional targetable liposomal drug delivery system in the management of leukemia: Potential, opportunities, and emerging strategies. **2023**, 325, 121771